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ABSTRACT
After heart disease, cancer is the leading cause of death in the U.S. According to the
National Cancer Institute, approximately 38% of the population will be diagnosed with
cancer at some point over the course of their life. This number is only expected to increase
with the increased age of the general public due to medical progress, leading to an increased
importance in finding effective and convenient treatment that can be used across a wide
array of cancers.

In theory, any tumor can be destroyed using enough of a cytotoxic method, whether it be
heating, radiation, surgery, or chemotherapy. However, because cancer c ells are derived
from a person’s own healthy cells mutating, all of these treatments involve destroying
healthy tissue in the process. Because of this, the most important aspect of any treatment
modality is its tumor specificity: the ability of the treatment to target cancerous tissue vs.
healthy tissue. The higher the ratio of cancer cell death to healthy cell death a treatment
contains, the more effectively it can be used in clinical practice.

A common method of targeting cancerous tissues is by targetin g biomarkers that are
overexpressed in cancer cells. These can include utilizing antibody, receptor, or vitamin
bindings. While these methods can increase the specificity of treatment, there are also
associated shortcomings with them. They tend to be cell-line specific, so a treatment that
may work for one strain of cancer may not have the desired effect across other lines. Even
within a single cancer strain, there exists heterogeneity a tumor, resulting in some cells not
expressing the biomarkers to the extent needed for adequate targeting. This not only results

in some cells surviving damage, but those cells then go on to reproduce, passing on their
traits, and causing the tumor to adapt to become more resistant to that treatment. Within
this arises the need to target a more general biomarker presented throughout all cancer cells
and strains.

In 1931, the Nobel Prize in Physiology was awarded to Dr. Otto Heinrich Warburg for his
discovery of what is known as the Warburg effect. In his research, Dr. Warburg discovered
that even in the presence of oxygen, cancerous tissue produces the majority of its energy
via anaerobic glycolysis instead of the aerobic oxidative phosphorylation. Glycolysis is a
much less efficient, but faster, process, resulting in an excess of positively charged
hydrogen ion byproducts. These are pumped outside of the cell memb rane to maintain a
normal pH within the cell, which results in a low pH environment immediately
extracellularly to cancerous tissue. This acidity at the surface of cancer cells is ubiquitous
across solid tumors, making it an ideal biomarker to target for cancer treatment.

pH-Low Insertion Peptide (pHLIP) is a pH-dependent peptide, whose pH-dependent action
is based on the protonation of the aspartic (Asp) and glutamic (Glu) acid residues at tge Cterminal end of the peptide. In the presence of a low pH env ironment, the normally
negatively charged Asp and Glu residues of pHLIP become protonated, increasing the
overall hydrophobicity of the polypeptide. In the presence of a lipid bilayer, it triggers the
insertion of the peptide across the bilayer to form a transmembrane alpha helix. Because
of the Warburg effect described above, the acidity surrounding a cancerous tissue therefor
promotes selective insertion of pHLIP across the cell membrane of tumor cells. As a result,

different cargoes can be attached to the peptide, consequently being either tethered or
translocated across membrane of cells in acidic diseased tissue at much higher proportions
than in healthy tissue.

The main goal of this work was to evaluate the efficacy of different pHLIP variants to
target tumors and deliver cargo across the membrane for therapeutic and
diagnostic/imaging applications. In therapeutic applications, the attached cargo would
directly induce cell death via external radiation enhancement, cell heating, or radioactive
emission. For this, gold nanoparticles (GNPs) were studied, as gold is an inert and
biocompatible. The focus of this work was to create GNPs coated with pHLIP to allow for
enhancement of radiation via Auger electron emission, and to explore the possibility of
creating gold-coated bicelles for heating via plasmon resonance. For diagnostic and
imaging applications, the attached cargo would be used to visually differentiate the
cancerous and healthy tissue, and be used in coordination with therapeutic strategies such
as surgery for treatment. For this, the near-infrared dye indocyanine green (ICG) was
conjugated to pHLIP to make ICG-pHLIP. ICG is already used in clinics for fluorescence
guided surgery for imaging of lymph nodes and blood flow, making ICG-pHLIPs transition
to clinics more straightforward and efficient. The focus of this study was to find the ICGpHLIPs selectivity to cancerous tissue in vivo in balb-c and nude mice, exploring proof of
concept for its continuation into human trials.
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PREFACE
This dissertation is written in “Manuscript” format, using the Thesis/Dissertation template
of the University of Rhode Island. There are three manuscripts included in this dissertation,
each of which comprises a chapter. The tables and figures of each manuscript are listed
under the corresponding chapter in the list of tables and figures.

The results of our studies presented in the first two chapters were published in the following
papers:
1. Wyatt L, Moshnikova A, Crawford TM, Engelman DM, Andreev OA, Reshetnyak
YK. New pHLIPs for the Targeted Intracellular Delivery of Cargo Molecules to
Tumors. PNAS (2018)
2. Daniels JL, Crawford TM, Andreev OA, and Reshetnyak YK. Synthesis and
Characterization of pHLIP® Coated Gold Nanoparticles. Biochem Biophys Rep
(2017)
The final chapter is composed of research that has been submitted for publication:
3. Crawford TM, Moshnikova A, Roles S, Weerakkody D, DuPont M, Carter LM,
Shen J, Engelman D, Lewis JS, Andreev OA, Rehestnyak YK. ICG pHLIP: A
Novel Agent for Fluorescence-Guided Surgery. Manuscript submitted for
publication.
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Abstract
The pH (low) insertion peptides (pHLIPs) target acidity at the surfaces of cancer cells and
show utility in a wide range of applications, including tumor imaging and intracellular
delivery of therapeutic agents. Here we report pHLIP constructs that significantly improve
the targeted delivery of agents into tumor cells. The investigated constructs include pHLIP
bundles (conjugates consisting of two or four pHLIP peptides linked by polyethylene
glycol) and Var3 pHLIPs containing either the nonstandard amino acid, γ-carboxyglutamic
acid, or a glycine−leucine−leucine motif. The performance of the constructs in vitro and in
vivo was compared with previous pHLIP variants. A wide range of experiments was performed on nine constructs including (i) biophysical measurements using steady -state and
kinetic fluorescence, circular dichroism, and oriented circular dichroism to study the pHdependent insertion of pHLIP variants across the membrane lipid bilayer; (ii) cell viability
assays to gauge the pH-dependent potency of peptide-toxin constructs by assessing the
intracellular delivery of the polar, cell- impermeable cargo molecule amanitin at
physiological and low pH (pH 7.4 and 6.0, respectively); and (iii) tumor targeting and
biodistribution measurements using fluorophore-peptide conjugates in a breast cancer
mouse model. The main principles of the design of pHLIP variants for a range of medical
applications are discussed.
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Introduction
The targeted delivery of drugs to cancer cells promises to maximize their therapeutic
effects while reducing side effects. Although many biomarkers exist that can be exploited
to improve tumor targeting and treatment outcomes, such as various receptors
overexpressed at the surfaces of some cancer cells, useful markers are not present in all
tumors. Further, the heterogeneity of the cancer cell population in an individual tumor and
between tumors of various patients limits the effective use of biomarker targeting
technologies, and rapid mutation increases the likelihood of the selection of cancer cell
phenotypes that do not express high levels of the targeted biomarker. Thus, biomarker
targeting can act as a selection method that may lead to the development of drug resistance
and poor patient outcomes (1–3).
It is well known that acidosis is ubiquitous in tumors, including both primary tumors and
metastases, as a consequence of their rapid metabolism (4). The acidic microenvironment
is generated by the increased use of glycolysis by cancer cells, and by the ab undance of
carbonic anhydrase proteins on the cancer cell surfaces. Tumor cells stabilize their
cytoplasmic pH by exporting the acidity to the extracellular environment. As a result of the
flux and the membrane potential, the extracellular pH is lowest at the surfaces of cancer
cells, where it is significantly lower than normal physiological pH and the bulk
extracellular pH in tumors (5–7). The low pH region persists at the cancer cell surface even
in well-perfused tumor areas. The acidity on the surfaces of cancer cells is a targetable
characteristic that is not subject to clonal selection, and the level of acidity is a predictor of
tumor invasion and aggression, since more rapidly growing tumor cells are more acidic.
The emerging technology based on pH (low) insertion peptides (pHLIPs) comprises a
variety of acidity-targeting peptides, each possessing different tumor-targeting
characteristics. The pHLIPs can be used in a wide variety of applications, so it is desirable
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to have a range of options for specific applications. Some examples of these applications
include (i) fluorescence imaging (8–10) and fluorescence image-guided surgery (11); (ii)
nuclear imaging including PET and SPECT (single-photon emission computed
tomography) (12, 13); (iii) therapeutic applications such as the targeted delivery of polar
toxins that cannot cross cell membranes (14, 15), drug-like molecules that inherently
diffuse across cell membranes (16, 17), and gene therapy (18); and (iv) nanotechnology for
enhancing the delivery of gold nanoparticles (19, 20) or liposome-encapsulated payloads
to cancer cells (21).
The pHLIPs are triggered to insert across the membranes of cancer cells by the acidity at
the cancer cell surface. The behavior of peptides in the pHLIP family is typically described
in terms of three states: at physiological pH (pH 7.4), peptides exist in equilibrium between
a solvated state (state I) and a membrane- adsorbed state (state II); a decrease in pH shifts
the equilibrium toward a membrane-inserted state (state III) (22). The mechanism
Results
pHLIP constructs. We investigated nine pHLIP variants; among them are Var3/Gla (with
nonstandard amino acid Gla), Var3/GLL (with glycine−leucine−leucine motif), and pHLIP
bundles (Table 1). The pHLIP bundles consist of two- or four- armed polyethylene glycol
(PEG) 2-kDa spacers conjugated to the cysteine residue at the N terminus of WT: PEG2WT and PEG-4WT, respectively (Fig. 1 A and B). Our motivation is to increase both the
membrane affinity and the cooperativity of the transition from the membrane-surface state
to the membrane- inserted state. Enhancement of affinity is expected to improve targeting,
and higher cooperativity should narrow the window of pH that produces TM drug delivery.
The information about all pHLIP variants used in the study with additional variations from
the addition of single N- or C-terminal cysteine or lysine residues for conjugation purposes
is provided in Tables S1 and S2. Nine pHLIP variants can be grouped together in various
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ways by shared characteristics. A WT-like group contains peptides with two protonatable
residues (shown in bold in Table 1) in the putative TM region, multiple protonatable
residues in the membrane-inserting C-terminal region, and two tryptophan residues
(residue W) both located at the beginning of the helix- forming TM region; this group
includes WT, PEG-2WT and PEG-4WT, WT/Gla, and WT/Gla/Aad. A Var3-like group is
based on Var3 from the first pHLIP series (25). This group includes Var3, Var3/Gla, and
Var3/GLL, each of which have three protonatable residues in the TM region and
tryptophan residues located at the beginning and end of the TM region. Considering this
scheme, ATRAM, with its multiple glycine and leucine residues and single tryptophan
located about two-thirds to the end of its TM part, is in a group of its own. Other subgroups
can be considered as well: a subgroup of peptides that incorporate the nonstandard Gla
residue, shown in italics in Table 1 (i.e., WT/Gla, WT/Gla/Aad, and Var3/Gla), and another
subgroup that includes peptides containing the GLL motif (Var3/GLL and ATRAM).
When performing analysis of biophysical measurements, analyzing variants with respect
to their group mates becomes important: The very different characteristics of peptides from
various groups make it difficult to accurately compare the behavior of all peptides at the
same time.

Biophysical steady-state and kinetics studies. A variety of spectroscopic techniques were
employed to probe the interaction between pHLIP variants and 1 -palmitoyl-2-oleoyl-snglycero-3-phosphocholine (POPC) phospholipid bilayers in liposomes; these techniques
included steady-state fluorescence spectroscopy, circular dichroism (CD), oriented circular
dichroism (OCD),

and

stopped-flow fluorescence measurements. Steady-state

fluorescence and CD experiments were conducted in phosphate buffer titrated with
hydrochloric acid to drop the pH from pH 8 to pH 4 to ensure consistency with previously
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published data (25, 29, 30). Steady- state and kinetics fluorescence experiments measuring
the pH- dependent transition from state II to state III were carried out in phosphate buffer
containing the physiological concentrations of free calcium (1.25 mM) and magnesium
(0.65 mM) ions found in blood, since we expected that some of the constructs might bind
these ions.
We established that, in solution, PEG-2WT and PEG-4WT most probably exist in compact
coil conformations, where tryptophan and other aromatic residues can form stacking
structures. The resulting exciton formation was seen as a minimum around 230 nm in the
CD spectra of these pHLIP bundles (Fig. 1 E and F). At pH 8, changes in the tryptophan
fluorescence show that both constructs interact with the lipid bilayer, and it appears that
PEG-4WT exhibits stronger binding than PEG-2WT in state II. With a reduction of pH,
both pHLIP bundles inserted into the bilayer to form helices, and the TM orientations of
these helices were confirmed by OCD measurements (Fig. 1 G and H). It is important to
note that, in state III, the membrane-inserted state, the exciton signal generated by π−π
stacking is no longer present, suggesting that the insertion of each pHLIP renders it in dependent of the other(s). The pK of the transition from state II to state III was shifted to
pH 6.6, and, as might be expected, the cooperativity of the transition was increased for
PEG-4WT compared with PEG-2WT (Fig. 1 I and J).
We compared the groups consisting of WT, Var3, and ATRAM pHLIP variants to the
newly designed Var3/Gla and Var3/GLL pHLIP variants. The HPLC retention times of the
peptides indicate increasing hydrophobicity within the groups in the following order, from
less to more hydrophobic: WT, WT/Gla, WT/Gla/Aad and Var3, Var/Gla, Var3/GLL, and
ATRAM, with ATRAM being the most hydrophobic (Table S2). Both new pHLIP variants,
Var3/Gla and Var3/GLL, demonstrated a pH-dependent interaction with the membrane
(Fig. S1). Var3/GLL showed a higher percentage of membrane-inserted population at pH
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8, which reflects a higher affinity of the peptide for the lipid bilayer both at physiological
and high pH due to the increased hydrophobicity of the peptide.
As seen for previous pHLIP designs, a blue shift (or decrease in Stokes shift) resulting
from the environmental changes from state I to state II and state III was observed for all
peptides (Table S3), indicating partitioning of the peptides into the lipid bilayer. However,
we cannot directly compare the positions of fluorescence spectra maxima for peptides
belonging to the different groups, since the locations of the tryptophan residues within the
peptides varies greatly. With this fact in mind, we can conclude that the peptides had very
different conformations in state II at pH 8, and that the highest membrane affinity was
exhibited by the PEG-pHLIPs and by the WT/Gla/Aad, Var3/ GLL, and ATRAM peptides.
The PEG-pHLIPs have multiple binding sites due to the linking of multiple WT peptides
within a single construct, which is expected to enhance binding affinity. The WT/Gla/Aad,
Var3/GLL, and ATRAM have the most hydrophobic sequences, and thus exhibit strong
binding/insertion. We also found that some peptides were especially sensitive to the
presence of calcium and magnesium ions, namely WT, variants containing the Gla residue
(WT/Gla, WT/Gla/Aad, and Var3/ Gla), and ATRAM. This sensitivity was most obviously
seen as a decreased Stokes shift (usually 2 nm to 3 nm) in state I and/or state II, and might
reflect slight increases in the hydrophobicity of the peptides caused by the coordination of
divalent cations resulting from the presence of closely spaced protonatable residues, such
as those found in the C-terminal region of WT and, to some degree, in ATRAM, or to the
presence of the Gla residue, with its two protonatable carboxyl groups, in the WT/Gla, WT/
Gla/Aad, and Var3/Gla peptides. It is known that a Gla residue can form a complex with a
calcium ion (31–33). The decrease in Stokes shift in state II is likely due to the location of
membrane- adsorbed peptides deeper in the lipid membrane (especially for the more
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hydrophobic pHLIPs: WT/Gla/Aad, Var3/GLL, and ATRAM) and/or a shift in peptide
population from the solvated to the membrane-adsorbed state.
In contrast to tryptophan fluorescence changes, which are de- pendent on the location of
tryptophan residues within the peptide sequence, the appearance of helicity is a more
general parameter which can be compared among all peptides. In Fig. 2A (and Table S3),
we give the ratio of ellipticity at 205 nm to 222 nm, an indicator of the degree of helicity
(lower ratios indicate higher helicity), obtained for different peptides in different states. In
state I, the lowest ratios were observed for pHLIP bundles, which correlate with the
appearance of the exciton signal at 230 nm. In state II, the most structured peptides (ratios
< 1.5) were PEG- 4WT, WT/Gla/Aad, Var3/GLL, ATRAM, and PEG-2WT, which
exhibited a higher affinity to the membrane and an increase in the peptide-inserted
population at pH 8. At low pH, all peptides exhibited similar helical content, as expected
from the formation of TM helices.
The transitions from state II to state III seen in steady-state and kinetics modes exhibited
pK values in the range of pH 5.7 to 6.6 in the presence of physiological concentrations of
calcium and magnesium ions, with the highest cooperativity observed for PEG-4WT, and
transition times varying from 0.1 s to 37.5 s (Table 2). There are subtleties that affect the
comparison and interpretation of the data such as: (i) The peptides are in different starting
conditions in state II at pH 8 due to greatly dif fering overall peptide hydrophobicity; (ii)
difference in peptides pK values, which reflect equilibrium between peptides’ mem- braneadsorbed and membrane-inserted populations; (iii) characteristic times, which report the
movement of tryptophan residues into environments inside the membrane; however, since
the tryptophan residues are located in different regions of each pHLIP, their movement into
the membrane, as measured via changes in fluorescence parameters, should be expected to
be different; and (iv) the cooperativity of the transition is a some-
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what unstable parameter in the fitting of experimental pH- dependence data using the
Henderson−Hasselbalch equation, especially if slopes are introduced at the initiation and
completion of the transition (34). Lower values of cooperativity (n < 1) were observed for
the peptides with tryptophan residues located at (Var3 group) or close (ATRAM) to the C
terminus, which must be translocated across the cell membrane. ATRAM and Var3/GLL,
which are the most hydrophobic pHLIPs and are therefore likely to be located more deeply
than others in the membrane at pH 8, demonstrated the fastest times of insertion. As we
showed previously, the removal of protonatable residues from the inserting C terminus
increases the rate of the transition from state II to state III (24, 25). Thus, the group of
Var3-like peptides exhibited fast insertion times (t < 1 s), a characteristic most attributable
to the presence of less protonatable residues in the Var3-like peptides as well as a decrease
in the number of these residues located at the C-terminal ends of the peptides. In the group
of WT peptides, the time of insertion decreased as the hydrophobicity of the peptide
increased, with insertion times listed in the following order (from longest to shortest time
of insertion): WT, WT/Gla, WT/Gla/Aad, PEG-2WT, and PEG-4WT.
Intracellular delivery of polar cargo. We asked whether the pHLIP bundles could cause
any acute cytotoxicity by themselves. HeLa cells were treated with either PEG-2WT or
PEG-4WT at physiological pH (pH 7.4) and low pH (pH 6.0) for 2 h. We did not observe
any cytotoxic effect at either pH, even when treating with concentrations up to 10 μM
(construct concentration is presented as concentration of WT pHLIP).
A proliferation assay was employed to evaluate the ability of pHLIPs to deliver the
amanitin toxin, a relatively cell-impermeable, polar cargo molecule (35, 36). For amanitin
to induce cytotoxicity, it must be translocated across the cell membrane, be released from
the peptide carrier, and reach its target in the nucleus (RNA polymerase II). Amanitin was
conjugated via a cleavable disulfide link to the inserting, C termini of the peptides. The
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translocation capabilities of the pHLIP-amanitin conjugates were measured as the
inhibition of proliferation of HeLa cells treated with increasing concentrations (up to 2 μM)
of pHLIP-amanitin at either physio- logical pH (pH 7.4) or low pH (pH 6.0) for 2 h,
followed by removal of the constructs, transfer of cells to normal cell culture media, and
assessment of cell death at 48 h.
Each of the conjugates demonstrated pH-dependent cytotoxicity (Fig. S2). The calculated
EC20, EC50, and EC80 at physio- logical and low pH are shown in Table 2. At low pH,
the most potent constructs were the pHLIP bundles, which exhibited the highest
cooperativity of transition from membrane-adsorbed to membrane-inserted states. The
least toxic at normal pH among all constructs was Var3. Fig. 2B lists the therapeutic
indexes (TIs), defined as the ratio of EC50 at pH 7.4 to EC50 at pH 6.0 for each case. A TI
of about 9 was obtained for WT/Gla and Var3, and the TI was around 5.5 for PEG-2WT,
Var3/Gla, and ATRAM. It is desirable to have high potency, which is defined as a
difference between cell viability at low and physiological pHs at different concentrations
of the construct (Fig. 3). All constructs had high potency (60 to 70%) at particular
concentrations; however, just a few constructs, namely Var3, Var3/Gla, and WT/ Gla, had
a high, stable potency over a wide range of concentrations. The pHLIP bundles displayed
the highest potency at the lowest concentrations (0.1 μM to 0.2 μM). The potency of
ATRAM peaked at concentrations around 0.5 μM and declined sharply at higher
concentrations; this decline is most likely associated with the increased hydrophobicity of
ATRAM, which results in a high affinity for the cell membrane at normal and high pH and
promotes the shift in equilibrium toward the membrane-inserted form that is associated
with the translocation of cargo across the cell membrane.
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Tumor targeting. To evaluate the tumor targeting and bio- distribution characteristics of
the pHLIP variants, we conjugated the fluorescent dye Alexa Fluor 546 (AF546) to the
noninserting, N termini of seven of the peptides. Our previous data indicate excellent tumor
targeting by AF546-pHLIPs (9, 27). In the case of pHLIP bundles, AF546 was conjugated
to the inserting, C termini of the PEG-2WT and PEG-4WT pHLIPs, as the N termini were
occupied by PEG polymers. A well-established mouse model, using implanted cells of
acidic 4T1 murine breast tumors, was used in the study; this model is targeted well by
pHLIPs (9, 27). Following the development of breast tumors in the mouse flank, each
fluorescent construct was introduced by a single tail vein injection. Animals were killed 4
h after the injection of the fluorescent conjugates, and the tumor and major organs (kidney,
liver, lungs, spleen, and muscle) were collected and imaged. We selected the 4 -h
postinjection time point based on previous pharmacokinetics data which show that the
highest tumor targeting with pHLIPs is observed 4 h after the injection of construct (9, 27).
The mean values of the surface fluorescence intensity of tumors, muscle, and organs are
given in Table S4. The normalized tumor fluorescence intensity (normalized by tumor
uptake of AF546-WT) for all constructs is shown in Fig. 4A. The highest tumor targeting
was observed for the Var3 construct, as well as for Var3/Gla and ATRAM. The tumor
uptakes of the WT and Var3/GLL constructs were significantly reduced, by 1.6 - and 2.6fold, respectively, compared with the uptake of Var3. The uptakes of WT/Gla,
WT/Gla/Aad, and the pHLIP bundles were reduced even further compared with the uptake
of the WT construct. It is possible that the decreased tumor targeting observed in the PEGpHLIP bundles might be attributed to the fact that the AF546 dye was conjugated to the C
terminus, which is translocated into the cytosol. At the same time, the tumor-to-muscle
ratio of the WT-like group was in the range of 5.4 to 7.5. The highest tumor-to-muscle
ratios were observed for Var3 (T/M = 8.9) and PEG-2WT (T/ M = 7.5), and the lowest
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ratio was observed in Var3/GLL (T/ M = 4.0) (Fig. 4B and Table S5). Among all
constructs, only Var3/GLL demonstrated a tumor-to-kidney ratio less than 1 (Fig. 4C and
Table S5). The highest tumor-to-liver ratio was found in Var3 and Var3/Gla (Fig. 4D and
Table S5).
Because PEG-2WT-AF546 and PEG-4WT-AF546 are several times larger than the other
pHLIP variants, we expected that they might have slower pharmacokinetics. Therefore, we
also performed imaging at the 24-h postinjection time point for the two PEG-pHLIP
conjugates; however, we did not observe any significant signal increase in tu mors at 24 h
postinjection compared with 4 h postinjection (Table S4).

Discussion

To advance cancer therapy using a range of agents with different prop erties, we have
developed new versions of pHLIP variants and pHLIP bundles, and compared their
performance to the performance of recently introduced variants with nonstandard amino
acids (Gla and Aad) and the hydrophobic GLL motif. Our goal was to correlate the
biophysical properties of the membrane interactions of different pHLIPs, including
physiological concentrations of free calcium and magnesium ions, to the ability of these
pHLIPs to move polar cargo across the cell membrane and to target acidic tumors.
The thermodynamic parameters of pK and cooperativity of pH-dependent transition from
State II at pH 8 to State III at pH < 5 can be taken as predictors of the performance of a
pHLIP for drug delivery and tumor targeting (17, 28, 29). While pK is a rather stable fitting
parameter, the cooperativity parameter (Hill coefficient) might vary over a wide range
resulting from different fittings which are within the level of accuracy of the experimental
measurements. Moreover, if different binding affinities are assumed, the Hill formulation
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loses validity. In general, highly cooperative transitions are hard to measure in biological
systems with noise, especially when examining relatively short peptides like the class of
pHLIP peptides (28). Only if the biological system is approximated to be infinite can a
phase transition occur (37). Moreover, transition parameters for different peptides can only
be truly compared when both peptides have precisely the same starting and ending states;
although this condition is met for the membrane-inserted state (state III) of the peptides,
which appears very similar among pHLIP variants, the condition that the initial state (state
II) of the peptides be identical is not met. As hydrophobicity varies widely among peptides
of the pHLIP family due to the difference in numbers of protonatable, polar, and
hydrophobic residues and their location within the peptide sequences, the characteristics of
the peptide population in the initial state of the transition also varies as these peptides
position themselves at different interaction levels with the hydrophobic/hydrophilic
boundary region of a bilayer.
The population percentages of inserted peptide presented in Table S6 were calculated from
the pH-dependent transitions of pHLIP variants. The numbers represent the percentage of
membrane-inserted peptides at varying pH assuming that, at the beginning of the transition
(state II) (i.e., at physiological pH and higher), the population of inserted peptides is close
to zero. In reality, close consideration of the interaction between a pHLIP variant and the
membrane at pH 8, in conditions more alkaline than physiological conditions where the
inserted peptide population should be even less than at physiological conditions, indicates
that the most hydrophobic sequences, such as ATRAM and Var3/GLL, and bundled
pHLIPs with multiple binding sites within a single construct, exhibit a significant inserted
peptide population, as shown by the loss of pH-dependent differences in the translocation
of the polar, cell-impermeable cargo amanitin with an increase in construct concentration
(i.e., a decrease in potency at higher concentrations). Additionally, as previously shown
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using the pore-forming peptide melittin, helix formation, membrane binding, and insertion
properties are very sensitive to primary structure changes involving glycine and leucine
residues (38). Ultimately, due to patient variability, it is highly desirable that potential
therapeutic pHLIP constructs are able to discriminate between healthy and tumor tissue
over a wide concentration range, meaning that a constant potency is necessary to avoid
targeting normal tissue and the resulting significant side ef fects, suggesting that the
properties of these variants may not be well suited for clinical development using agents
that require tight targeting.
In addition to the steady-state experiments, it is important to probe tumor targeting and to
examine the biodistribution of the constructs when injected into the high-flow-rate blood
stream, since targeted delivery is always opposed by clearance from the blood. The best
tumor targeting was shown by faster-inserting pHLIP constructs. Thus, in the design of
new pHLIP variants, the biophysical kinetics parameters need to be considered in addition
to the more traditionally prioritized steady-state properties. These kinetics parameters
might be especially critical for the delivery and translocation of a cargo across a membrane,
since we have shown that charges and the presence of cargo at the inserting end of a pHLIP
can slow the process of insertion (24). Different cargoes linked to a pHLIP alter
biodistribution and tumor targeting (27). Less polar pHLIP variants conjugated with
hydrophobic cargoes might have a higher tendency toward targeting normal tissue and
hepatic clearance. On the other hand, the size of links in pHLIP bundles could be used to
tune biodistribution and redirect clearance from renal to hepatic.
Among the pHLIP variants we investigated, Var3 demonstrated excellent performance in
vitro (the most stable potency over a wide range of concentrations) and high tumor
targeting. Variants containing the Gla residue, especially the WT/Gla construct, showed an
increase in the cooperativity of the membrane insertion transition as previously reported
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(28), and showed an improved TI. However, the tumor targeting of WT/Gla was lower
compared with the tumor targeting of WT.
The γ-carboxyglutamic acid is not naturally encoded in the human genome, but is
introduced into proteins through the posttranslational carboxylation modification of
glutamic acid, resulting in an amino acid with two carboxyl groups. Several proteins are
known to have Gla-rich domains, including many coagulation factors, which coordinate
calcium ions, inducing conformational changes in the proteins that enhance the
hydrophobicity and affinity of the proteins to the cell membrane bilayer (39). Calcium
complex formation by a pHLIP increases the hydrophobicity of the peptid e and alters the
interaction be- tween peptide and membrane; this fact, along with the fact that the cost of
synthesizing a Gla-containing peptide is very high (Gla is one of the most expensive amino
acids) might somewhat reduce enthusiasm in using the Gla residue, but, if there were
sufficient advantages in a specific case, the cost might be justified. While considering
peptide synthesis, it is worthwhile to note that very hydrophobic pHLIP sequences (like
ATRAM), especially when coupled with even moderately hydrophobic cargoes, might be
challenging to produce in the large quantities needed for clinical translation.
There is no single recipe for the best pHLIP: The peptide will need to be tailored to each
specific medical application. For example, kidney clearance might be preferred to liver
clearance for PET-pHLIP imaging constructs (13). High tumor-to-normal tissue
fluorescence intensity ratios will be the key in fluorescence-guided surgical applications
(11). Delivery of highly toxic molecules, such as amanitin, would require minimal offtargeting; thus high potency and TI will be critical. However, for the delivery of polar
peptide nucleic acids or other highly specific inhibitors of particular pathways in cancer
cells, neither of which are associated with toxicity in normal cells, the requirement to
reduce off- targeting might be much lower, and the emphasis would be shifted toward the
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efficiency of delivery, the goal being to translocate as much cargo as possible (18, 40). The
pHLIP bundles might yield excellent results in these types of applications, supported by
the observation that PEG-4WT is the most efficient at delivering the polar molecule
amanitin to the intracellular space. We believe that bundling multiple Var3 pHLIPs, in the
same fashion that we linked two or four WT pHLIPs, might be more advantageous. Var3
demonstrates membrane insertion rates orders of magnitude faster than the insertion rates
of WT; with the knowledge that faster insertion rates observed in biophysical experiments
correlate to better tumor targeting in vivo, it stands to reason that potential PEG-Var3
constructs might demonstrate better tumor targeting still.
In drug delivery applications, pHLIP peptides are best designed for the delivery of polar,
cell-impermeable molecules (14, 35, 41, 42). The intracellular delivery of a polar cargo
could be further tuned by altering the link connecting the cargo to pHLIP and/or by
attaching modulator molecules to the inserting end of the peptide (14, 15, 18, 35).
Additionally, pHLIP could be used for the targeted delivery of cell-permeable, drug-like
molecules since it can significantly increase the time of retention in blood, positively alter
the biodistribution of drugs that typically rely on passive diffusion, and enhance tumor
targeting, all of which would lead to an increase in TI (16). More polar pHLIP variants are
expected to be better suited to applications involving the intracellular delivery of cellpermeable cargoes.
We have now established a set of properties for a number of pHLIPs, which can be selected
as starting points for clinical development in different circumstances. This body of work,
with the prior studies, opens pathways for targeted delivery using a range of imaging and
therapeutic agents in the fight against cancer.
Materials and Methods
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pHLIP characterization and pHLIP bundle synthesis. All peptides were purchased
from CS Bio Co. Peptides were characterized by reversed phase high -performance liquid
chromatography (RP-HPLC) using Zorbax SB-C18 and Zorbax SB-C8, 4.6 × 250 mm, 5
μm columns (Agilent Technology). For biophysical measurements, PEG-2WT and PEG4WT were made by conjugating either 2 kDa bifunctional maleimide-PEG-maleimide or 2
kDa 4-arm PEG-maleimide (Creative PEGWorks) to Cys-WT via an N-terminal cysteine
residue. Purification of the PEG-pHLIP constructs was conducted using RP-HPLC. Peptide
concentration was calculated by absorbance at 280 nm, where, for WT, WT/Gla, and
WT/Gla/Aad, ε280 = 13,940 M-1 cm-1; for Var3, Var3/Gla, and Var3/GLL, ε280 = 12,660 M1

cm-1; and for ATRAM, ε280 = 5,690 M-1 cm-1. PEG construct concentration was presented

in terms of peptide concentration, not molecular concentration.

Liposome preparation. Small unilamellar vesicles were used as model membranes and
were prepared by extrusion. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC;
Avanti Polar Lipids) was dissolved in chloroform at a concentration of 12.5 mg/mL, then
desolvated by rotary evaporation for two hours under vacuum. The resulting POPC film
was rehydrated in 10 mM phosphate buffer at pH 8, either with additional calcium and
magnesium ions (1.25 mM calcium and 0.65 mM magnesium), or without additional ions,
vortexed, and extruded fifteen times through a membrane with a pore size of 50 nm.

Steady-state fluorescence measurements. Steady-state fluorescence spectra were
measured using a PC1 spectrofluorometer (ISS) with temperature control set to 25.0 °C.
The tryptophan fluorescence was excited using an excitation wavelength of 295 nm.
Excitation and emission slits were set to 8 nm, and excitation and emission polarizers were
set to 54.7° and 0.0°, respectively. Sample preparation was conducted 24 hours prior to
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experiments to allow for State II equilibration. A buffer-only sample was used as a baseline
for State I, and a buffer-with-POPC-only sample was used as a baseline for States II and
III.

pH dependence measurements. Measurements of pH dependence were taken with the
PC1 spectrofluorometer by using the shift in the position of maximum of peptide
fluorescence as an indication of changes of the peptide environment at varying pH. All pH
dependence measurements were conducted using blood physiological concentrations of
free calcium and magnesium ions (1.25 and 0.65 mM, respectively). After the addition of
hydrochloric acid, the pH of solutions containing 5 µM peptide and 1 mM POPC were
measured using an Orion PerHecT ROSS Combination pH Micro Electrode and an Orion
Dual Star pH and ISE Benchtop Meter (Thermo Fisher Scientific) before and after
spectrum measurement to ensure equilibration. The tryptophan fluorescence spectrum at
each pH was recorded, and the spectra were analyzed using the Protein Fluorescence and
Structural Toolkit (PFAST) (42) to determine the positions of spectral maxima (𝜆max). The
position of 𝜆max was plotted as a function of pH and normalized, such that 𝜆initial
max −
position of spectral maximum in State II was set to 1 and 𝜆final
max − position of spectral
maximum in State III, was set to 0. The normalized pH-dependence was fit with the
Henderson-Hasselbach equation (using OriginLab software) to determine the cooperativity
(𝑛) and transition mid-point (p𝐾) of transition of the peptide population from State II to
State III:

𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑝𝐻 𝑑𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑐𝑒 =

1
1+10𝑛(pH−p𝐾)
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(1)

Steady-state circular dichroism and oriented CD measurements. Steady-state CD was
measured using an MOS-450 spectrometer (Bio-Logic Science Instruments) in the range
of 190 to 260 nm with a step size of 1 nm, and with temperature control set to 25.0 °C.
Samples were prepared 24 hours prior to experiments to allow for State II equilibration. A
buffer-only sample was used as baseline for State I, and a buffer-with-POPC-only sample
was used as baseline for States II and III.
OCD was measured using supported planar POPC bilayers prepared using a
Langmuir-Blodgett system (KSV Nima). Fourteen quartz slides with 0.2 mm spacers were
used; after sonicating the slides in 5% cuvette cleaner (Contrad 70; Decon Labs) in
deionized water (≥18.2 MΩ cm at 25 °C; Milli-Q Type 1 Ultrapure Water System, EMD
Millipore) for fifteen minutes and rinsing with deionized water, the slides were immersed
and sonicated for ten minutes in 2-propanol, sonicated again for ten minutes in acetone,
sonicated a final time in 2-propanol for ten minutes, and rinsed thoroughly with deionized
water. Lastly, the slides were immersed in a 3:1 solution of sulfuric acid to hydrogen
peroxide for five minutes and rinsed three times in deionized water. The slides were stored
in deionized water until they were used. POPC bilayers were deposited on the fourteen
slides using a Langmuir-Blodgett minitrough: a 2.5 mg/mL solution of POPC in
chloroform was spread on the subphase (deionized water) and the chloroform was allowed
to evaporate for fifteen minutes, after which the POPC monolayer was comp ressed to 32
mN/m. A lipid monolayer was deposited on the slides by retrieving them from the
subphase, after which a solution of 10 µM peptide and 500 µM of 50 nm POPC liposomes
at pH 4 was added to the slides, resulting in the creation of the supported bilayer by fusion
between the monolayer on the slides and the peptide-laden lipid vesicles. After incubation
for six hours at 100% humidity, the slides were rinsed with buffer solution to remove excess
liposomes, and the spaces between the cuvettes were filled with buffer at pH 4.
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Measurements were taken at three points during the experiment: immediately after the
addition of the peptide/lipid solution (0 h), after the slides were rinsed to remove excess
liposomes following the six-hour incubation time (6 h), and after an additional twelve-hour
incubation time and rinse with buffer (18 h); these measurements were recorded on the
MOS-450 spectrometer with sampling times of two seconds at each wavelength. Control
measurements were conducted using a peptide solution between slides without supported
bilayers and in the presence of POPC liposomes.

Kinetics measurements. Stopped-flow fluorescence measurements were made using an
SFM-300 mixing system (Bio-Logic Science Instruments) in conjunction with the MOS450 spectrometer. All solutions were degassed for fifteen minutes prior to loading into the
stopped-flow system. pHLIP variants were incubated with POPC for 24 hours prior to the
experiment to reach State II equilibrium, and insertion was induced by mixing equal
volumes of pHLIP/POPC solutions with hydrochloric acid diluted to ensure a pH drop from
pH 8 to pH 4. Kinetics data were fit by one-, two-, three-, or four-state exponential models
in OriginLab.

Amanitin pHLIP conjugates. α-amanitin (Sigma-Aldrich) was conjugated to
succinimidyl 3-(2-piridyldithio)propionate) (SPDP; Thermo Fisher Scientific), followed
by purification and conjugation of the SPDP-amanitin to the C-terminal cysteine residues
of pHLIP peptides. For synthesis of PEG-2WT-amanitin and PEG-4WT-amanitin, LysWT-Cys with N-terminal lysine and C-terminal cysteine residues was used, and the LysWT-SPDP-amanitin was conjugated to dibenzocyclooctyne-sulfo-N-hydroxysuccinimidyl
ester (DBCO-NHS ester; Sigma-Aldrich), resulting in DBCO-WT-SPDP-amanitin.
Finally, 2-arm or 4-arm PEG-azide (Creative PEGWorks) was conjugated to DBCO-WT-
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SPDP-amanitin, resulting in PEG-DBCO-WT-SPDP-amanitin, with a cleavable disulfide
bond present in SPDP, between the peptide and amanitin cargo. Construct concentration
was calculated by absorbance at 310 nm, where, for α-amanitin, ε310 = 13,000 M-1 cm-1.
Construct concentration was presented in terms of peptide/amanitin concentration.
Purification was conducted using RP-HPLC. Zorbax SB-C18 columns (9.4 × 250 mm, 5
µm; Agilent Technologies) were used for all peptide-amanitin conjugates other than
ATRAM-amanitin, PEG-2WT-amanitin, and PEG-4WT-amanitin, for which Zorbax SBC8 columns (9.4 × 250 mm, 5 µm; Agilent Technologies) were used.

Cell proliferation assay. Human cervix adenocarcinoma cells (HeLa; American Type
Culture Collection) were authenticated, stored according to the instructions of the supplier,
and used within three months of frozen aliquot resuscitation. Cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich) at pH 7.4 with 4.5 g/L Dglucose, supplemented with 10% heat-inactivated fetal bovine serum (FBS; SigmaAldrich) and 10 µg/mL ciprofloxacin (Sigma-Aldrich), in a humidified atmosphere of 5%
CO2 and 95% air at 37 °C. The pH 6.0 medium was prepared by mixing 13.3 g of dry
DMEM in 1 L of deionized water. HeLa cells were loaded in the wells of 96 -well plates
(5,000 cells/well) and incubated overnight. The standard growth medium was replaced with
medium without FBS, at pH 6.0 or 7.4, containing increasing amounts of pHLIP-amanitin
conjugates (from 0 to 2.0 µM). Treatment with amanitin alone for two hours and at
concentrations up to 2 µM does not induce cell death (35). After two-hour incubation with
the pHLIP-amanitin conjugates, the constructs were removed and replaced with standard
growth medium. Cell viability was assessed after 48 hours using the CellTiter 96 AQ ueous
One Solution Cell Proliferation Assay (Promega); the colorimetric reagent was added to
cells for one hour, followed by absorption measurement at 490 nm. All samples were
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prepared in triplicate, and each experiment was repeated between 3 and 6 times. All
obtained cell proliferation data were normalized by corresponding controls (non -treated
cells). There was no difference in the viability of cells incubated with media, without
construct, at pH 7.4 and pH 6.0; therefore, the role of pH was excluded from the
consideration. Normalized cell viability data obtained in different experiments were
averaged and presented in terms of the logarithm of dose of pHLIP-amanitin constructs.
The dose-response function was used for fitting the obtained data (Figure S2) (OriginLab):

𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 𝐴𝑏 +

𝐴𝑡 −𝐴𝑏

(2)

1+10𝑝(log 𝑥0−𝑥 )

where 𝐴𝑏 and 𝐴𝑡 are the bottom and the top asymptotes, respectively. The top asymptote
was set as constant (100%) while for the bottom asymptote we allowed small variations in
the range of 0 to 10%. 𝑝 is the slope (cooperativity parameter) and log 𝑥0 is the center of
the transition (i.e., the concentration for half response) which is used to calculate the EC20,
EC50, EC80 values:

𝐸𝐶20 = 10

(log𝑥0 +log0.25⁄𝑝)

(3)

𝐸𝐶50 = 10 log𝑥0

𝐸𝐶80 = 10

(4)

(log𝑥0 +log4⁄𝑝)

(5)

Therapeutic index (TI) was calculated according to the equation:
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p𝐻 7.4

𝑇𝐼 =

𝐸𝐶50

(6)

p𝐻 6.0

𝐸𝐶50

Additionally, the cytotoxicity of the PEG-2WT and PEG-4WT constructs without amanitin
was tested: these experiments demonstrated no cytotoxicity at physiological or low pH at
treatment concentrations up to 10 µM.

Fluorescent pHLIP conjugates. Alexa Fluor 546 (AF546) C5 maleimide (Thermo Fisher
Scientific) was conjugated to the N-terminal cysteine residues of WT, Var3, Var3/Gla, and
ATRAM. AF546 NHS Ester (Thermo Fisher Scientific) was conjugated to the N-terminal
lysine residues of WT/Gla, WT/Gla/Aad, and Var3/GLL. For PEG-2WT and PEG-4WT,
Cys-WT-Lys, with N-terminal cysteine and C-terminal lysine residues, was used, and was
first conjugated to 2-arm maleimide-PEG-maleimide or 4-arm PEG-maleimide resulting in
PEG-WT-Lys. Then, AF546 NHS Ester was conjugated to the C-terminal lysine residue,
resulting in 2-arm and 4-arm PEG-pHLIP constructs with C-terminal AF546 fluorophores.
Construct concentration was calculated by absorbance at 554 nm, where, for AF546, ε554
= 93,000 M-1 cm-1. Construct concentration was presented in terms of AF546/peptide
concentration, not molecular concentration. Purification was conducted using RP-HPLC
for all peptides other than PEG-4WT-AF546, which was purified via Amicon Ultra
MWCO 10 kDa centrifugal filter (Sigma-Aldrich). Zorbax SB-C18 columns (9.4 × 250
mm, 5 µm; Agilent Technologies) were used for all AF546-peptide conjugates except
AF546-ATRAM and PEG-2WT-AF546, for which Zorbax SB-C8 columns (9.4 × 250 mm,
5 µm; Agilent Technologies) were used.

Ex vivo imaging. All animal studies were conducted according to the animal protocol
AN04-12-011 approved by the Institutional Animal Care and Use Committee at the
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University of Rhode Island, in compliance with the principles and procedures outlined by
the National Institutes of Health for the care and use of animals. Mouse mammary cells
(4T1; American Type Culture Collection) were subcutaneously implanted in the right flank
(8 × 10 5 cells/0.1 mL/flank) of adult female BALB/cAnNHsd mice (Envigo). When tumors
reached approximately 5-6 mm in diameter, single tail vein injections of 100 µL, 40 µM
fluorophore-pHLIP solutions in PBS were performed. Mice were euthanized 4 or 24 hours
after injection, and necropsy was immediately performed. Tumors and major organs were
cut in half and imaged using an FX Kodak in-vivo image station connected to an Andor
CCD camera. Mean surface fluorescence intensity of tumor, tissue and organs was obtained
via analysis of fluorescence images in ImageJ (NIH) (43). The corresponding
autofluorescence signal was subtracted to obtain the net fluorescence intensities used in the
study. Autofluorescence was calculated after imaging tumors, tissue, and organs collected
from mice with no injection of fluorescent pHLIP constructs.
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TABLES
Table 1. List of pHLIP sequences used in the study.
Peptide
Cys-WT
WT-Cys
Lys-WT-Cys
Lys-WT/Gla-Cys
Lys-WT/Gla/Aad-Cys
Cys-Var3
Var3-Cys
Cys-Var3/Gla
Var3/Gla-Cys
Lys-Var3/GLL-Cys
Cys-ATRAM
ATRAM-Cys

Sequence
ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT
AEQNPIYWARYADWLFTTPLLLLDLALLVDADEGCT
Ac-AKEQNPIYWARYADWLFTTPLLLLDLALLVDADECT
Ac-AKEQNPIYWARYAGlaWLFTTPLLLLDLALLVDADECT
Ac-AKEQNPIYWARYAGlaWLFTTPLLLLAadLALLVDADECT
ACDDQNPWRAYLDLLFPTDTLLLDLLWA
ADDQNPWRAYLDLLFPTDTLLLDLLWCA
ACDDQNPWRAYLGlaLLFPTDTLLLDLLWG
ADDQNPWRAYLGlaLLFPTDTLLLDLLWCG
Ac-GKEEQNPWLGAYLDLLFPLELLGLLELGLWCG
ACGLAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGN
GLAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGNCA
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Table 2. The midpoint (pK), cooperativity (n), and time (t) parameters characterizing the
pH-dependent transition of pHLIP variants in the presence of POPC liposomes are
presented. EC20, EC50, and EC80 values were calculated for each pHLIP-amanitin construct
at physiological and low pH by analyzing the pH- and concentration-dependent cell
viability data (Figure S2).

pK

n

t (s)

WT

6.5

1.8

36.8

EC20 (µM)
pH 7.4 pH 6.0
1.95
1.22

WT/Gla
WT/Gla/Aad
PEG-2WT
PEG-4WT
Var3
Var3/Gla
Var3/GLL
ATRAM

6.2
6.6
6.6
6.6
5.7
6.3
6.6
6.4

1.5
1.4
1.8
2.2
0.9
0.7
0.4
0.9

37.5
34.8
18.8
13.1
0.9
0.7
0.1
0.1

6.20
3.01
1.98
0.473
10.63
5.12
1.75
2.06

Peptide

0.93
0.66
0.54
0.19
1.30
1.34
0.47
0.40
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EC50 (µM)
pH 7.4
pH 6.0
1.37
0.56
2.73
1.39
1.03
0.33
3.95
2.76
0.91
1.23

0.30
0.37
0.19
0.11
0.43
0.50
0.23
0.22

EC80 (µM)
pH 7.4 pH 6.0
0.96
0.26
1.20
0.64
0.53
0.23
1.47
1.48
0.47
0.74

0.10
0.21
0.07
0.06
0.14
0.19
0.11
0.12

FIGURES

Figure 1. Schematic organization of pHLIP bundles: (a) PEG-2WT with 2 kDa 2-arm PEG
and two WT pHLIPs, and (b) PEG-4WT with 2 kDa 4-arm PEG and four WT pHLIPs.
Transitions between the three states of PEG-2WT and PEG-4WT in phosphate buffer at
pH 8 (State I), in the presence of POPC liposomes at pH 8 (State II), and in the presence
of liposomes at pH 4 (State III) were monitored by changes of tryptophan fluorescence (c
and d), circular dichroism (e and f), and oriented circular dichroism (OCD) (g and h)
signals. Normalized pH-dependent steady-state transitions from State II to State III were
examined by analyzing the shift in position of fluorescence spectrum maximum of PEG2WT (i) and PEG-4WT (j) in the presence of physiological concentrations of calcium and
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magnesium ions. The data were fitted using the Henderson-Hasselbalch equation; the
fitting curves and 95% confidence interval are shown by red and blue lines, respectively.

Figure 2. Ellipticity ratios of CD signals at 205 nm to 222 nm are shown for pHLIP variants
in State I, II, and III (a). The values of ellipticity ratios are given in Table S3. The
therapeutic index (TI) was calculated for different pHLIP-amanitin constructs as the ratio
of EC50 at pH 7.4 to EC50 at pH 6.0 (b).

33

Figure 3. pH-dependent potency was defined as the difference between cancer cell
viability when cells were incubated at pH 7.4 and pH 6.0 at varying concentrations of
different pHLIP-amanitin constructs. The WT-like group is shown in (a); the Var3-like
group and ATRAM are shown in (b).
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Figure 4. Normalized tumor fluorescence intensities of the AF546-pHLIP constructs are
shown; the signals were normalized by the tumor intensity of AF546 -WT (a). Tumor-tomuscle (T/M) (b), tumor-to-kidney (T/K) (c), and tumor-to-liver (T/L) (d) fluorescence
intensity ratios are shown. Statistically significant differences were determined by twotailed unpaired Student’s t-test, where * denotes p ≤0.05 and ** denotes p ≤0.005.
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Abstract
Novel approaches in synthesis of spherical and multispiked gold nanoparticles coated
with polyethylene glycol (PEG) and pH Low Insertion Peptide (pHLIP®) were
introduced. The presence of a tumor-targeting pHLIP® peptide in the nanoparticle
coating enhances the stability of particles in solution and promotes a pH -dependent
cellular uptake. The spherical particles were prepared with sodium citrate as a gold
reducing agent to form particles of 7.0 ± 2.5 nm in mean metallic core diameter and
∼43 nm in mean hydrodynamic diameter. The
particles that were injected into tumors in mice (21 µg of gold) were homogeneo usly
distributed within a tumor mass with no staining of the muscle tissue adjacent to the
tumor. Up to 30% of the injected gold dose remained within the tumor one hour postinjection. The multispiked gold nanoparticles with a mean metallic core diameter of
146.0 ± 50.4 nm and a mean hydrodynamic size of ~161 nm were prepared using
ascorbic acid as a reducing agent and disk-like bicelles as a template. Only the presence
of a soft template, like bicelles, ensured the appearance of spiked nanoparticles with
resonance in the near infrared region. The irradiation of spiked gold nanoparticles by
an 805 nm laser led to the time- and concentration-dependent increase of temperature.
Both pHLIP® and PEG coated gold spherical and multispiked nanoparticles might ﬁnd
application in radiation and thermal therapies of tumors.

Introduction
Gold nanoparticles (ranging in size from 1 to 200 nm) might ﬁnd various applications
in medicine including the enhancement of x-ray radiation damage to tumor tissues [1–
4] and the induction of localized heating in photothermal therapy [5–7]. The latter is
achieved when gold nanoparticles are exposed to light and impart heat energy to their
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local environment due to the temporary existence and decay of localized surface
plasmon polaritons. In addition of use of gold nanoparticles, also supermagnetic
nanoparticles are developed for magnetic resonance imaging and hyperthermia to
induce cancer cells death or promote drug release [8–13]. In all cases of nanoparticle
use, not only should the particles be stable, but they should preferentially target
diseased tissue, such as a cancerous tumor.
Many contemporary therapeutic and imaging approaches to cancer treatment rely on
tumor-targeting biomarkers such as antibody technologies or vitamin binding [14–18].
Although there are signiﬁcant successes, the inter- and intra-heterogeneity of tumors,
their complexity, and their ability to adapt to new conditions often create parts of a
tumor that may not express enough of the biomarker to be targeted. This results in the
regrowth of resistant tumors and poor therapeutic outcomes, where the average
improvements in survival are measured in months. At the same time, there is an
emerging body of evidence indicating that the acidity of the tumor tissue plays a key
role in determining cancer cell invasiveness and resistance to therapies.

Tumors

exhibit marked heterogeneity due to genetic alterations, which lead to the modiﬁcation
of biochemical pathways. The modiﬁcations that result from metabolic alterations,
lead to a surge in extracellular acidity. Tumor cells adapt to this acid-induced toxic
environment by stimulating proteins that regulate intracellular homeostasis [19,20].
Among pH-targeting agents, the family of pH Low Insertion Peptides (pHLIP®) ﬁnd
a broad range of applications in biomedical sciences. pHLIP® peptides insert across
cellular membranes in a pH-dependent manner, with one terminus exposed to the
extracellular space and the other terminus to the cytoplasm [21 –24]. The molecular
mechanism of a pHLIP® peptide's action is based on the protonation of Asp/Glu
residues, which enhances the peptide's hydrophobicity and promotes membrane -
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associated folding with the insertion of a transmembrane helix [25,26]. It was shown
that pHLIP® peptides are excellent at targeting acidic tumors, which allows for the
speciﬁc delivery of imaging and therapeutic agents to cancer cells within tumors
[22,27–29]. The number and variety of pHLIP® based nanomedicines is growing. For
example, the coating of lipid-based, polymeric, and metallic nanoparticles with
pHLIP® peptides enhances the targeting of acidic tumors and the number of particles
internalization within cancer cells [30–36].
We have shown speciﬁc tumor accumulation of gold nanoclusters of
1.4 nm in diameter conjugated to the pHLIP® peptide [37], and an enhancement of
radiation eﬀect observed for cancer cells treated with pHLIP® gold nanoclusters [38].
As well, novel photo-induced pHLIP® coated hollow gold nanospheres containing
chlorine 6 were introduced recently [33,34].
hyperthermia

The

nanospheres

experience

within 5 min of laser exposure, which leads to the release of

photosensitizers due to the reduction of electrostatic interaction. While the obtained
results are very interesting and promising, there are aspects which require
improvement and justify further work: i) the coating of gold nanoclusters conjugated
with pHLIP® peptide should be improved to avoid particles aggregation; and ii) a
greater amount of gold might be needed in tumors to observe a signiﬁcant radiation
enhancement eﬀect. Therefore, here we introduce novel approaches for synthesis of
pHLIP® and PEG coated spherical and spiked gold nanoparticles for the enhancement
of radiation damage and near infrared (NIR) thermal therapy.

Materials and Methods

2.1.

Materials for synthesis of pHLIP® and PEG coated gold nanoparticles
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Gold III chloride, 5% solution, was purchased from Salt Lake Metals (Salt Lake City,
UT). Sodium citrate tribasic, L-ascorbic acid, and urea dehydrate were purchased from
Sigma-Aldrich Co. (St. Louis, MO). The wild type (WT) pHLIP® peptide:
ACEQNPIYWARYADWLFTTPLLLLDLALLVDADET
was synthesized and puriﬁed by C.S. Bio Co. (Menlo Park, CA), and the concentration
of the peptide was determined by absorbance at 280 nm (ε=13,940 M−1 cm−1). The
m-polyethylene glycol–SH (mPEG- SH), about 5 kDa in mass, was purchased from
Creative PEGworks (Chapel Hill, NC). The lipids, 1,2-dihexanoyl-sn-glycero-3 phosphocholine, D6PC; 1,2-diheptanoyl-sn-glycero-3-phosphocholine, D7PC/D HPC
and 1,2-dimyristoyl-sn-glycero-3-phosphocholine,

DMPC were purchased from

Avanti Polar Lipids, Inc (Alabaster, AL). Tris-(2-carbox- yethyl) phosphine
hydrochloride (TCEP) was purchased from Thermo Fisher Scientiﬁc (Waltham, MA).
The procedures for synthesis of the spherical and multispiked pHLIP® and PEG coated
gold nanoparticle are described in the Results section.

2.2.

Bicelle preparation

Bicelles were prepared by thin-ﬁlm method: a chloroform solution of DMPC and
D7PC (DHPC) lipids were dried using a rotary evaporator producing an even thin ﬁlm,
followed by the additional overnight evaporation under a high vacuum to remove
traces of organic solvents. The lipid layer was re-suspended in 10 mM phosphate buﬀer
pH 6.5 and underwent ten freeze-thaw-vortex cycles using liquid nitrogen and a warm
bath (40 °C).
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2.3.

Puriﬁcation of gold nanoparticles

To remove large particles (in the case of spherical gold nanoparticles) and excess
reducing agents, the ﬁnal solution of particles under- went two forms of ﬁltration.
Large particles were removed using centrifugation (5 min at 10,000 relative centrifugal
force, RCF).

Excess

reducing

agents

were

removed

by

size-exclusion

chromatography using sephadex G25 fast spin columns. 500 μL of particles were
added to 5 mL of sephadex G25 gel ﬁltration beads (Sigma-Aldrich Co.) (the beads
were hydrated in the desired buﬀer) and centrifuged for 0.5 min increments at roughly
36 RCF. The ﬁnal nanoparticle solutions were passed through a 0.2 µm sterile
Acrodisk® syringe ﬁlter with HT Tuﬀryn® membrane (Pall Life Sciences) f or
sterilization when experiments on cultured cells and mice were carried out, as well as
for stability studies and heating experiments.

2.4.

UV–visible absorption spectroscopy

The absorbance of gold nanoparticles was recorded on a Genesys 10S UV–Vis
Spectrophotometer to establish the wavelength range of resonance.

2.5.

Measurements of particles size

The size of bicelles and gold nanoparticles in solution was measured by dynamic light
scattering (DLS) using a Zetasizer Nano ZS (Malvern) instrument and a nanoparticle
tracking system, Nanosight (NS300, Malvern), respectively. Tran smission electron
microscopy (TEM) (JEOL 2100) with an accelerating voltage of 200 kV at
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magniﬁcations in the range of 10,000× to 150,000× was u sed to image gold
nanoparticles to establish the shape, size, and homogeneity of the particles. Samples
were prepared for TEM by drying 5 μL of the nanoparticle solution on a carbon type B, 300 mesh, copper grid (Ted Pella, Inc). Size histograms were averaged and ﬁtted
with a Gaussian function.

2.6.

ICP-MS analysis

The investigated samples (cells, tumor tissue, or nanoparticles in solution) were
dissolved in a concentrated solution of aqua regia (1:3 volume ratio of nitric acid and
hydrochloric acid) and sonicated. The ﬁnal solutions were diluted to 2% (wt/vol) nitric
acid with distilled water and centrif uged to remove organic tissue. The gold content
was quantiﬁed using inductively coupled plasma mass spectrometry (ICP- MS)
(Thermo scientiﬁc X7 series and Thermo X-Series 2 quadrupole) by using calibration
standards IMS 103 (UltraScientiﬁc).

2.7.

Heating

In a poly(methyl methacrylate) (PMMA) cuvette (with a 4.5 mm window width and
12.5 mm depth), 300 μL of solution was illuminated by an 805 nm temperature
controlled laser diode with 500 mW output (TCLDM9, Thorlabs). The solution
temperature was measured every
minute with an immobilized FLIR E6 thermal imager (FLIR Systems, Inc.) from above
to avoid obstruction by the cuvette walls. A sample of phosphate -buﬀered saline
(PBS), pH 7.4, was illuminated and used as a baseline.
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2.8.

Cancer cells

JC murine mammary-gland adenocarcinoma cells were obtained from the American
Type Culture Collection (ATCC). The cells were cultured in Roswell Park Memorial
Institute (RPMI) medium supplemented with 10% fetal bovine serum (FBS) and 10
μg/mL ciproﬂoxacin in a humidiﬁed atmosphere of 5% CO2 and 95% air at 37 °C.

2.9.

Cytotoxicity assay

JC cancer cells were seated in a 96-well plate (3000–3500 cells per well in 100 μL
RPMI medium) and incubated overnight. The next day, 100 μL of gold nanoparticles
in PBS pH 7.4 supplemented with 10 mM D-glucose were added to the cells at two
concentrations and incubated for 48 h. Final gold concentrations after addition to cells
were 0.025 g/ L and 0.013 g/L (spherical particles) 0.010 g/L and 0.005 g/L (multi spiked particles). Cell viability was assessed by a colorimetric reagent (CellTiter 96
AQueous One Solution Assay, Promega), which was added to cells for one hour
followed by the measurement of absorbance at 490 nm by an iMark Microplate
Absorbance Reader (Bio-Rad Laboratories, Inc.). The absorbance readings were
corrected for the absorbance of gold nanoparticles at 490 n m. All samples were
prepared in triplicate.

2.10. Cellular uptake of gold nanoparticles
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Various amounts of JC cancer cells (from 100,000 to 1 million cells in diﬀerent
experiments) were treated in suspension with puriﬁed spherical gold nanoparticles
(0.83% citrate and 10% pHLIP-90% PEG) (typically the ﬁnal concentration of gold
with cells was 0.06 g/L) for three hours at 37 °C in serum-free Leibovitz's L-15
medium of pH 6.0 or pH 7.4 (ﬁnal treatment volume was 500 μL). In another
experiment, JC cells were pre-treated with gold nanoparticles in serum-free L-15
medium at pH 7.4 for 20 min, and then media (with diﬀerent pHs) were added to set
a total volume of 500 μL and a ﬁnal solution pH of 7.4 or 6.0–6.2. After treatment,
samples were pelleted (5 min at 600 RCF) and washed with PBS, pH 7.4, three times.
The amount of gold in each pellet was then quantiﬁed using ICP-MS. The amount of
gold not taken up by cells was quantiﬁed in the supernatant by absorbance
measurements. Control samples of gold nanoparticles without cells and cells without
particles were investigated at both high and low pH as well. All samples were prepared
in triplicate.

2.11. Uptake and distribution of gold in tumors

All animal studies were conducted according to the animal protocol AN07 -01-015
approved by the Institutional Animal Care and Use Committee at the University of
Rhode Island, in compliance with the principles and procedures outlined in the
National Institutes of Health Guide for the Care and Use of Animals. Female Balb/C
mice ranging in age from 4 to 6 weeks and weighing from 18 to 22 g were obtained
from Envigo RMS, Inc; 16 mice were used in the study.Tumors were established in
the right ﬂank by subcutaneous injection of JC cancer cells (106 cells in 100 μL).
After about two weeks, 50 μL of 0.11 g/L of puriﬁed spherical gold nanoparticles
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(0.83% citrate and 10%

pHLIP-90% PEG) (5.5 µg of gold), or 0.42 g/L gold

particles (21 µg of gold) in PBS, pH 7.4, supplemented with 10 mM D-glucose were
injected intratumorally. An hour after injection, mice were euthanized and the tumors
were immediately collected for histological and gold-quantiﬁcation analysis. The
amount of gold in each tumor was quantiﬁed using ICP-MS. A non-injected mouse
with a similar-sized tumor was used as a negative control. The distribution of gold
within the tumor was assessed by white light imaging of the tumor center.

2.12. Histological staining and imaging of tumor sections

Immediately after tumors were collected from the mice, they were frozen in tissue -tek
OCT compound using liquid nitrogen and stored at −80 °C until sectioned at a
thickness of 20 µm using a cryostat at −25 °C (Vibratome UltraPro5000, GMI).
Tumor sections were then ﬁxed in a 4% paraformaldehyde solution (Sigma-Aldrich
Co.), washed three times with deionized water, permeated with 0.3% Triton X -100
(Sigma-Aldrich, Co.) in PBS, pH 7.4, for one hour, washed two times with deionized
water, and stained with HQ Silver™ silver enhancement solution (Nanoprobes, Inc)
for 15 min followed by a ﬁnal washing. The tumor sections were ﬁnally stained with
3 μM 4′,6-diamidino-2-pheny-lindole (DAPI) (Molecular Probes, Thermo Fisher
Scientiﬁc) for two and a half hours to mark cell nuclei. Adjacent tumor slides were
ﬁxed in 4% formaldehyde and stained with hematoxylin and eosin (H & E) (Thermo
Fisher Scientiﬁc and Poly Scientiﬁc R & D Corp). The stained section was covered
with a drop of mounting medium (Permount®, Fisher Scientiﬁc) and then a cover slid e
was placed over the medium. The slides were examined under an inverted ﬂuorescence
microscope (IX71 Olympus).
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Results

We have synthesized and investigated pHLIP® and PEG coated gold nanoparticles. In
our study we used WT pHLIP® peptide (4.1 kDa) with a single Cys residue at the N terminus and similar size of PEG polymer (about 5 kDa) with a single SH group. The
pHLIP® and PEG were used in a mixture with reducing agents, tri-sodium citrate or
ascorbic acid, to prepare spherical or spiked gold nanoparticles, respectively. The
pHLIP® peptide was dissolved in a solution of 2.7 M urea and mixed (in equal parts)
with degassed, deionized water containing a ten times molar-excess of TCEP, which
prevents the formation of disulﬁde bonds. The PEG polymer was dissolved in
degassed, deionized water containing a ten times molar-excess of TCEP.

3.1. Synthesis and characterization of spherical pHLIP® and PEG coated gold
nanoparticles

To obtain pHLIP® and PEG coated spherical gold nanoparticles, the solution of gold
III chloride was reduced using tri-sodium citrate mixed with pHLIP® peptide and PEG
polymer. The solution containing gold III chloride, citrate, pHLIP®, and PEG was
blown with argon and sealed for incubation at room temperature. Within 15 –20 min a
change in color of the solution was observed (Supplementary Fig. S1) and particles
were left overnight at room temperature to ensure the complete reduction of the gold
and coating of nanoparticles by pHLIP® and PEG. Interesting to note that presence of
pHLIP® slows down time of gold reduction.
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In the course of this study we varied the amount of citrate, pHLIP®, and PEG, and
monitored the changes of nanoparticles size and absorbance of the nanoparticles
solution for the appearance of a resonance peak at 5 25 nm (Fig. 1). The absence of
pHLIP® and PEG leads to the aggregation of particles and precipitation within a
couple of hours after their preparation (Supplementary Fig. S1 and Fig. 1a). The higher
amount of citrate is expected to promote better stability of nanoparticles. However, our
goal was an investigation of formation of gold nanoparticles in the presence of
pHLIP® an PEG, which were found to enhance stability and solubility of
nanoparticles. The best resonance was observed when gold nanoparticles were coated
with both pHLIP® and PEG. The amount of sodium citrate was varied from 0.42% to
2.8% wt/vol in the presence of 10% pHLIP® and 90% PEG in solution, where the
concentration of citrate is reported as a ﬁnal concentration in the nanoparticle solution
(Fig. 1b). A low amount of citrate (0.42% wt/vol) in solution results in the shift and
broadening of the resonance peak, as well as the appearance of large particles, which
was conﬁrmed by the nanoparticle tracking system (data not shown). At the same time,
particle sizes did not change when the amount of citrate was varied from 0.83% wt/vol
to 2.8% wt/vol. The best results (narrow resonance) were obtained for citrate
concentrations in the range between 0.83% wt/vol and 1.7% wt/vol. There is a
possibility that at high amount of citrate (2.8% wt/vol) in the presence of pHLIP® and
PEG, the shape of particles might be altered, which leads to the broadening and shift
of a resonance.
The amount of pHLIP® peptide and PEG polymer was altered as well. An increased
percentage of negatively charged pHLIP®, which slows down process of gold
reduction, and decreased percentage of neutral PEG polymer leads to the broadening
of resonance and shift (by 6–8 nm) of resonance to longer wavelengths (Fig. 1c). The
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minimum amount of citrate (0.83% wt/vol), 10% pHLIP® and 90% PEG were chosen
as an optimal, when resonance is narrow and there are enough pHLIP® peptides
deposited to the surface of nanoparticles to preserve pH-dependent interaction of the
coated nanoparticles with the lipid bilayer of a membrane. The ﬁnal selected
composition of reagents (0.83% citrate and 10% pHLIP-90% PEG) comprised the
following molar parts: 0.5 parts of 10 mM gold III chloride; 0.075 parts of tri- sodium
citrate (10% wt/vol); 0.1125 parts of 0.5 mM PEG with 5 mM T CEP; 0.0125 parts 0.5
mM pHLIP® peptide with 5 mM TCEP and 1.35 M urea, and 0.3 parts of degassed
deionized water.
After synthesis, the solution of nanoparticles was puriﬁed to remove large particles
and excess reducing agents. The large particles were removed by centrifugation. The
excess reducing agents were removed when the nanoparticles were transferred to PBS,
pH 7.4 solution by size-exclusion chromatography. TEM imaging was employed to
analyze nanoparticle size and shape distributions (Fig. 1e). The nanoparticles were
homogeneous and round. The metallic core was about 7.0 ±2.5 nm in diameter
(Supplementary Fig. S2a). The mean hydrodynamic size (diameter), determined by
nanoparticle tracking system, was about 43 nm.
Puriﬁed spherical gold nanoparticles coated with pHLIP® and PEG (0.83% citrate and
10% pHLIP-90% PEG) were stable for at least 36 days at 4 °C in PBS, pH 7.4. The
stability of gold nanoparticles in solution was assessed by visual appearance of
precipitate, measurements of nanoparticle size and resonance peak by absorbance
recording. The stability study was carried out on the particles at two diﬀerent
concentrations with gold amount of 0.10 g/L and 0.02 g/L. A high stability proﬁle was
obtained for both concentrations (Fig. 1d). At the same time, when particles were
synthesized using a citrate reducing agent (low amount of citrate) containing only
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PEG, or without both PEG and pHLIP®, the stability was seriously compromised;
particles settled over time forming large visible aggregates and the resonance peak was
shifted and broadened (data not shown). Thus, the presence of pHLIP® peptide in gold
nanoparticles coating is essential to maintain colloidal stability over time when using
the methods described here.

3.2.

Templated synthesis and characterization of pHLIP® and PEG coated

multispiked gold nanoparticles

Another approach we explored in the preparation of pHLIP® and PEG coated gold
nanoparticles was based on use of bicelles as a soft template, to obtain irregularly
shaped nanoparticles. Bicelles are disk-like micelles, which consist of long-chain and
short-chain phospholipids or surfactants (Fig. 2a). The limitation in experiments using
bicelles is typically the high critical micelle concentration (CMC) of lipids and
detergents, which restricts the degree of bicelle dilution without the lipid phase
transforming to vesicles. For example, the CMC of the widely used short-chain D6PC
lipid is 14 mM. Thus, when the best characterized system of D6PC–DMPC bicelles
are diluted below CMC, they are expected to be converted into a mixture of free D6PC
lipids and DMPC lipid bilayer liposomes. It is known that D7PC lipids have a 10 times
lower CMC (1.4 mM), and D7PC–DMPC mixtures retain bicelle properties at
concentrations even as low as 0.1% wt/vol [39]. Therefore, we selected the DMPCD7PC lipid system and ensured that the addition of gold and reducing solutions does
not lead to the dilution of lipids below 0.1% wt/vol. Assuming the DMPC and DHPC
head groups occupy the same areas, the molar ratio of long-chain to short-chain lipids
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is expressed via q-values, which reﬂects diﬀerent aspect ratios of disk-like bicelles
[40,41]:
q = [DMPC] = 𝑞 =

[DMPC]
[𝐷𝐻𝑃𝐶 ]

=

2π R 2
πh (πR + h)

where R is the radius and h is the height of the bicelle (Fig. 2a). The height of the
bicelles in our study was 4.2 nm and the radius varied depending upon the ratio of
DMPC to DHPC lipids. The diameters of the bicelles of diﬀerent asymmetry, d(q),
calculated according to the above equation (without accounting for the DHPC capping)
are the following: d(0.2)=4.2 nm; d(0.3)=6.0 nm; d(0.5)=8.6 nm; d(0.75)=12 nm; and
d(1.0)=15 nm. To investigate the integrity of the D7PC-DMPC bicelle structures of
various aspect ratios, we monitored their change in size at concentrations of 1.0%,
0.5% and 0.1% wt/vol (Fig. 2b). Because we were only concerned with the change in
size upon dilution, no attempts were made to account for asymmetric particle sizes in
DLS measure- ments. A slight increase in size was observed at low concentrations
(0.1% wt/vol) for bicelles with q-values less than 0.75. On the other hand, highly
asymmetric bicelles with a q-value equal to 1 lose their structural integrity as a result
of dilution. Therefore, all experiments were performed with bicelles of q -values of
0.75 and lower.
Templated synthesis of pHLIP® and PEG coated multispiked gold nanoparticles was
always initiated shortly after bicelle preparation. We ensured that the addition of gold
solution and reducing agents does not lead to the dilution of the bicelle solution to lipid
concentrations less than 0.1% wt/vol. The following steps were performed in synthesis
of multispiked gold nanoparticles: i) a solution of gold III chloride was added to the
solution of bicelles and mixed; ii) next, the reducing agent, ascorbic acid, was added
very carefully; and iii) upon color change (~30s) the solution containing pHLIP® and
PEG was immediately added to complete the coating process. The appearance of NIR
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absorbance (Fig. 3a) along with TEM imaging (Fig. 3b) was indicative of the formation
of multispiked gold nanoparticles. In the absence of bicelles, the resonance shifted to
525 nm (Fig. 3a), reﬂecting the formation of solid spherical gold nanoparticles, which
was also conﬁrmed by TEM. Interestingly, the use of citrate as a reducer instead of
ascorbic acid shifts the equilibrium towards the formation of solid spherical gold
particles rather than the templated synthesis of spiked gold nanoparticles (data not
shown). The change of bicelle asymmetry (increase of q-values from 0.3 to 0.75) does
not aﬀect appearance of NIR resonance (Fig. 3a). Variation in the amount of gold in
the range from 1:0.5 to 1:3 lipid:gold ratios did not signiﬁcantly aﬀect the appearance
of the resonance peak. The normalized absorbance of nanoparticles does not change
upon dilution or the addition of a detergent that disrupts lipid structures, Triton X-100,
indicating nanoparticle stability and integrity after synthesis (data not shown). The
presence of pHLIP® and PEG resulted in the formation of particles that were more
stable in aqueous solution compared to the particles without coating, which were
precipitated shortly after their prepara- tion. The ﬁnal composition of the reagents was
the following molar parts: 0.05 part of 15 mM of lipids arranged into bicelles (> 0.1%
wt/ vol), 0.15 parts of 5 mM gold III chloride; 0.0225 parts of 250 mM ascorbic acid;
0.414 parts of 0.5 mM PEG with 5 mM TCEP; 0.046 parts 0.5 mM pHLIP® peptide
with 5 mM TCEP and 1.35 M urea; and 0.3175 parts of degassed, deionized water.
TEM imaging performed on ﬁltered pHLIP® and PEG coated gold nanoparticles
demonstrated the presence of irregular, multispiked gold nanoparticles (Fig. 3b). The
structures were the same for bicelles with diﬀerent q-values. Conversely, multispiked
structures were not observed in absence of bicelles. The mean core size (diameter) of
multispiked nanoparticles established by TEM was 146.0 ± 50.4 nm (Supplementary
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Fig. S2b). The mean hydrodynamic diameter, deter- mined by nanoparticle tracking
system, was about 161 nm.
Diﬀerent concentrations of pHLIP® and PEG coated multispiked gold nanoparticles
were illuminated in solution by an 805 nm laser diode with 500 mW output. The laser
radiant exposure was ~400 J/cm2. For particles at a concentration of 0.021 g/L gold, a
temperature increase of 14 degree units (from 26 °C to 40 °C) was observed within 5
min (Fig. 3c), which is ~18 J imparted to water or ~12% energy converted to heat.
More concentrated particles showed greater temperature changes at all time points
compared to less concentrated particles.

3.3.

Interaction of pHLIP® and PEG coated gold nanoparticles with cancer cells

First, we have tested the cytotoxicity of pHLIP® and PEG coated spherical and
multispiked gold nanoparticles. JC murine mammary-gland adenocarcinoma cells
were treated with gold nanoparticles (0.025 and 0.013 g/L of spherical; and 0.010 g/L
and 0.005 g/L of multispiked) for 48 h. The obtained results indicate that these gold
nanoparticles do not exhibit any cellular toxicity.
Next, we evaluated the pH-dependent cellular uptake of spherical gold nanoparticles
coated with pHLIP® and PEG. The experiment was performed several times and in
diﬀerent ways, such that the treatment of cells with gold nanoparticles was done at
neutral and low pH, or the pre-treatment of cells with gold nanoparticles was done at
neutral pH followed by the change of pH with media to low pH. All obtained data
indicate that the uptake of spherical gold nanoparticles coated with pHLIP® and PEG
by JC cancer cells at pH 6.0 was about 3 times higher than the uptake at neutral pH.
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The results conﬁrm the pH-dependent cellular uptake of gold nanoparticles coated with
pHLIP® and PEG.

3.4.

Distribution of pHLIP® and PEG coated gold nanoparticles within tumors

JC cancer cells were inoculated into the right ﬂank of mice by subcutaneous injection.
Spherical gold nanoparticles coated with pHLIP® and PEG were administered as a
single intra-tumoral injection at quantities of 5.5 and 21 μg gold. One hour after
injection, animals were sacriﬁced so that tumors could be collected and processed to
establish the amount of gold within and the distribution throughout a tumor. Among
all of the mice, there were animals with diﬀerent tumor masses that were separated
into 3 groups: 0.1, 0.3 and 0.4 g. The percentage of in jected dose accumulated within
the tumors increased with the increase of tumor mass: 16.2% for 0.1 g tumor; 18.0%
for 0.3 g, and 29.1% for 0.4 g of tumor (Supplementary Fig. S3). The mean tumor
uptake of gold (calculated for 8 animals) was 6.8 μg of gold p er gram of tumor (with
standard error of 1.6) when a total of 5.5 μg of gold was injected. The mean tumor
uptake of gold (calculated for 6 animals) was 24.5 μg/g (with standard error of 8.5)
when 21 μg of gold was injected. The highest accumulation of gold ∼47 μg/g was
found in the smallest tumors (85.0 ± 2.3 mg) injected with 21 μg of gold.
We also investigated the distribution of gold within the tumor mass. The white light
images were taken from the center of the tumor mass (Fig. 4a). Then, the frozen tum or
samples were sectioned and stained with H & E (Fig. 4b). The gold was distributed
nearly homogeneously within tumor mass except the right edge of the tumor with no
gold accumulation in the surrounding muscle. The muscle tissue adjacent to the tumor
is indicated by arrows on Fig. 4a and b, and a magniﬁed image of the border of the
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section containing both cancer cells and muscle is shown on Fig 4c. Adjacent sections
were treated with Triton to permeabilize the cellular membranes and then stained with
both a silver enhancement solution and DAPI. The representative images of the gold
enhanced by silver and stained nuclei are shown on Fig 4d-f.

Discussion

The motivation for our work was based on a desire to introduce stable pH -sensitive
pHLIP® and PEG coated gold nanoparticles with a potential translation to the clinic.
We developed methods for the preparation of spherical and multispiked gold
nanoparticles coated with pHLIP® and PEG, which might ﬁnd application in radiation
and NIR thermal therapies. The approach for the synthesis of spherical gold
nanoparticles coated with pHLIP® and PEG is very robust and can be implemented in
applied studies. The protocol for the preparation of multispiked gold nanoparticles
coated with pHLIP® and PEG could be further optimized, however the proof of
principle is established in our work. In both cases, pHLIP® peptide and PEG polymer
were used as components of the reducing solution (sodium citrate as a reducer in the
case of spherical nanoparticles and ascorbic acid in the ca se of multi- spiked
nanoparticles). The optimal combination of pHLIP® and PEG was selected to be 10%
and 90%, respectively. A decreased percentage of pHLIP® in the nanoparticle coating
might lead to the reduction of particle stability (resulting from the reduction of the
overall negative charge due to the presence of pHLIP® peptide on particle surfaces)
and the loss of pH-dependent properties. Previously, we investigated and showed the
utility of liposomes coated with diﬀerent quantities of pHLIP® and PEG [30,35]. It is
also possible to further optimize particles by employing a pHLIP® PEG conjugate
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instead of directly coating the surface with pHLIP®. Spherical gold nanopa rticles
coated with pHLIP® and PEG exhibited high stability in solution over a one month
time period, as opposed to the particles with no coating or just PEG coating. The PEG
coating was widely utilized in coating of various nanoparticles [42 –46]. The size of
the pHLIP® PEG coated particles’ metallic core was

in the range of 5 –8 nm in

diameter and the hydrodynamic size (diameter) of coated particles was in the range of
40–50 nm. The nanoparticles showed a pH-dependent uptake by cancer cells with no
signs of cytotoxicity. We performed intratumoral injections of spherical gold
nanoparticle solutions and investigated gold uptake and distribution within tumors at
one hour post-injection. It does not seem that there is any clinical utility to perform a
systemic administration of particles, since radiation therapy is typically delivered
locally and the location of the tumor is known from prior diagnostic imaging. Also,
there is a requirement to have as much gold as possible within a tumor (which could
be achieved only by local administration of the particles) to induce a radiation
enhancement eﬀect. The radiation delivered within a one hour time frame of particle
administration is expected to

be in line with clinical practice. Our results indicate

that gold nanoparticles (21 µg of injected gold) were distributed within the tumor mass
very well and with an overall uptake of 24.5 µg of gold per gram of tumor mass,
reaching values of 47 µg/g in tumors with masses of 1 g and less. This is a higher
uptake compared to that of pHLIP® gold nanoclusters [37]. We believe, the presence
of pHLIP® peptide in the coating of gold nanoparticles was crucial. The peptide
allowed particles to stay within the tumor and promoted the uptake of particles by
cancer cells at low extracellular pH, as we have shown previously [37,38]. At the same
time, particles were able to diﬀuse within a tumor as opposed to the direct injection of
micron-sized gold particles, that hinder tumor coverage by staying only at the injection
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site [3]. We also would like to outline that systemic administration of nanoparticles or
antibodies conjugated with gold nanoparticles results in staining of only the peripheral
tumor regions with limited penetration inside the tumor mass [47]. We did not observe
an accumulation of gold within the muscle tissue adjacent to the tumors. The amount
of injected gold in our study was much less than the amount of gold used in previous
radiation therapy studies on mice (see review and references within it) [48]. However,
we believe that the targeting of gold nanoparticles directed by pHLIP® peptide to the
vital cellular structures such as plasma and nuclear membranes could lead to the
enhancement of radiation eﬀects even at lower gold concentrations [38].
The spherical particles have the smallest surface to volume ratio for a given size of a
particle. The appearance of multiple sharp spikes or tips on the surface of nanoparticle
is known to give rise to the strong spatial conﬁnement of the electromagnetic ﬁeld,
since the core of a particle serves as a nanoscale antenna, increasing the excitation
cross section and the enhancement of the tip plasmon polaritons [49,50]. Various
approaches were introduced in the synthesis of star-like and multispiked gold
nanoparticles [50–53]. We used a soft template material of phospholipid bicelles to
synthesize pHLIP® and PEG coated multispiked gold nanoparticles. Bicelles, which
possess both low- and high- curvature regions within a bilayer disks, represent a class
of model membranes used in nuclear magnetic resonance (NMR) structural studies of
membrane biomolecules [41,54–56], but they have found additional applications in
biomedical sciences [57–59]. The bicellar templates were utilized previously to control
the growth of platinum with ascorbic acid as a reducer, producing metal nanodisks and
nanowheels [60,61]. Other phospholipid structures, like spherical liposomes, were also
used for gold deposition to assemble biodegradable plasmon resonant nanoshells,
which were used for the laser-induced release of molecules encapsulated into these
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liposomes [62–64]. Another approach was based on the assembly of liposomes and
micelles, called metallosomes, by using lipids conjugated with gold nanoclusters [65].
The presence of a soft template, like bicelles, in our reduction mixture induced the
formation of multispiked gold nanoparticles with plasmon resonance in the NIR range.
The absence of bicelles leads to the formation of spherical gold na noparticles with
absorbance at 525–560 nm. The size of gold multispiked nanoparticles established by
TEM imaging and nanoparticle tracking system was in the range of 100–170 nm and
130–200 nm, respectively. The heating of pHLIP® and PEG coated multispiked gold
nanoparticles in solution by an 805 nm laser diode led to the increase of the solution
temperature by 14 degrees within 5 min. Multispiked particles could be used in
combination with NIR laser treatment for photo-induced hyperthermia. It would be
very advantageous to employ lower power NIR laser radiation systems, which are
currently available for indocyanine green (ICG) imaging in clinical endoscopy and
laparoscopy (see table 4 for the description of IC G clinical imaging systems in the
review article) [66]. Also, due to the very high surface area of multispiked gold
nanoparticles, we envision their potential successful application for the enhancement
of x-ray radiation eﬀects. A number of binary radiation therapies are under
consideration [2,67–69]. At low photon energies, the most promising approach is
based on dose enhancement through Auger electron emission. Auger electron emission
generates a cascade of low energy electrons that travel short distances a nd deposit their
energy locally [70]. Thus, it is very important to deliver gold nanoparticles to vital
cellular structures, which pHLIP® helps achieve. Also, it was proposed th at a potential
advantage of the use of small gold nanoparticles (with an enhanced surface/volume
ratio) is the minimization of the energy of the Auger electrons deposited (lost) inside
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the gold nanoparticle [38,70]. Therefore, it could be very attractive to test multispiked
gold nanoparticles with large surface/volume ratios as radiation enhancers.
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Figures

Figure 1. Characterization of Spherical Gold Nanoparticles. The absorbance spectra
of the spherical gold nanoparticle solutions synthesized a) in the absence and presence
of pHLIP® peptide and/or PEG polymer or mixture of 10% pHLIP® and 90% PEG
(1.7% wt/vol citrate); b) with various amounts of sodium citrate, where the percentage
of citrate is reported as the ﬁnal wt/ vol concentration (10% pHLIP® and 90% PEG);
c) with various amounts of pHLIP® and PEG (0.83% wt/vol citrate). d) The
representative TEM images of pHLIP® and PEG coated spherical gold nanoparticles
obtained at 20,000× and 40,000x magniﬁcations (0.83% wt/vol citrate and 10%
pHLIP®−90% PEG). The size histograms of the metallic core of pHLIP® and PEG
coated nanoparticles is shown in Supplementary Fig. S2a. e) White light images of
particles at the beginning and end of stability studies (0.83% wt/vol citrate and 10%
pHLIP®−90% PEG, particles were puriﬁed and kept at 4 °C in PBS, pH 7.4).
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Figure 2. Structure of bicelles. a) The disk-like shape of a bicelle with height, h, and
radius, R, composed of DMPC and DHPC lipids. b) Dependence of bicelle size,
established by DLS, on its q- value, which is a ratio of long- to short-chain lipids
(reﬂecting the asymmetry of a bicelle).
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Figure 3. Characterization of Multispiked Gold Nanoparticles. a) The absorbance
spectra of gold nanoparticles obtained by gold reduced with ascorbic acid, pHLIP®,
and PEG in the absence and presence of bicelles of diﬀerent asymmetries. b) The
representative TEM image of pHLIP® and PEG coated multispiked gold nanoparticles
obtained at 12,000× magniﬁcation. The size histograms of the metallic core of pHLIP®
and PEG coated nanoparticles is shown in Supplementary Fig. S2b. c) The change in
temperature over time measured in solutions containing pHLIP® and PEG coated
spiked gold nanoparticles of diﬀerent concentrations irradiated by an 805 nm laser.
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Figure 4. Tumor Imaging of Spherical Gold Nanoparticle Uptake. a) The white light
image of a tumor center showing the gold distribution (after a 21 μg intratumoral
injection of pHLIP® and PEG coated spherical gold nanoparticles in PBS, pH7.4); b)
the section from the tumor center stained with H & E; and c) the magniﬁed image of
the tumor section outlined by a square in panel b, which shows tumor (T) and muscle
(M). The arrows on panels a and b indicate muscle tissue. d) The bright ﬁeld image of
tumor sections stained with silver enhancement solution and e) the ﬂuorescent image
of the same tumor section stained with DAPI to visualize cell nuclei; and f) an overlay
of the bright ﬁled and ﬂuorescent images. The percentage of injected dose of gold
accumulated within tumors of diﬀerent masses is given in the text and in
Supplementary Fig. S3.
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ABSTRACT
Fluorescence imaging has seen enduring use in imaging blood flow and is now finding
a new range of applications in image-guided surgery. In this paper, we report our
studies of a new fluorescent agent for use in surgery, ICG-pHLIP. Intravenously
administered ICG-pHLIP exhibits a multi-hour circulation half-life, offering
protracted delineation of vasculature. Concomitant with blood clearance, ICG -pHLIP
binds to cells in acidic tissues, such as tumors, by sensing cell surface acidity.
Accumulation in tumors marks them for surgical removal or other treatments. We
present the results of preclinical studies, including in vitro and in vivo efficacy,
pharmacology and toxicology investigations. It is found that ICG-pHLIP is non-toxic,
marks blood flow for hours after injection, and effectively marks tumors for improved
resection one day after administration.
In this paper, we explore applications of a new fluorescent agent for use in surgery,
ICG-pHLIP. Fluorescence imaging has long had applications in imaging blood flow
and is now finding a new range of applications in image-guided surgery. For decades,
fluorescence angiography has been applied to assess blood flow and tissue perfusion
in preoperative, intraoperative and postoperative settings 1-8. Emerging uses in
fluorescence-guided surgery promise to improve surgical outcomes by revealing tumor
margins and, even more importantly, by marking flat lesions and micro-metastases
adjacent to primary tumors, which are difficult to identify even by a very skilled
surgeon 9-12.
Several FDA approved fluorescent dyes and compounds are now in clinical use. 5 Aminolevulinic acid (5-ALA) and its derivatives are heme precursors that induce
production and intracellular accumulation of a fluorescent protoporphyrin. These dyes
are used intraoperatively to identify brain tumors such as malignant gliomas 13,14 and
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for fluorescent visualization of cancerous lesions in the bladder using blue light
cystoscopy after topical application of the agent by intravesical instillation 15-18. The
most widely used dye is the near infrared (NIR) emitting indocyanine green (ICG),
first approved for angiography and subsequently used in ophthalmology and elsewhere
for imaging blood vessels 19-24. In addition to clinically approved fluorescent
molecules, several approaches are under development (in preclinical and clinical trial
stages) for targeting and visualization of cancerous lesions intra- or post-operatively.
We have introduced a novel imaging agent, ICG-pHLIP, for the visualization of
cancerous lesions and blood flow during fluorescence-guided surgical procedures. A
pH-Low Insertion Peptide (pHLIPs ®1) senses elevated acidity at the surfaces of tumor
cells (or low surface pH, pH surf)25-27. Low pH promotes protonation of Asp/Glu
residues within pHLIP, increasing the peptide’s hydrophobicity and triggering the
peptide to form a stable helix across the membrane. By attachment to the N terminal
end of the peptide, which remains outside the cell, imaging probes can be tethered to
the surfaces of cells to mark tumors. Examples include PET or SPECT nuclear probes,
MR agents and fluorescence emitters. pHLIP offers a unique approach in the targeting
of a spectrum of tumor subtypes, as acidosis is a fundamental feature of the tumor
microenvironment28,29, and it has been found that pHLIP peptides conjugated with
various fluorescent dyes target tumors with high precision 30. ICG coupled to pHLIP
was chosen as a clinical candidate for two main reasons. Th e fluorescence of ICGpHLIP is enhanced about 20 times when pHLIP tethers ICG to the membrane
compared to the emission of ICG-pHLIP in aqueous solution, thus significantly
enhancing the tumor-to-background ratio 31. Also, many clinical instruments for
imaging of ICG fluorescence have already been developed and are clinically available,

1
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which potentially makes the adoption of ICG-pHLIP in the clinic a straightforward
process. Here we present the results of preclinical studies, including in vitro and in
vivo efficacy, pharmacology and toxicology investigations.

RESULTS
ICG-pHLIP Synthesis and Characterization
The 28-amino acid pHLIP Var3 peptide with free N- and C-terminus was synthesized
on solid support followed by purification and conjugation of a single Cys residue with
ICG-maleimide to obtain the ICG-pHLIP imaging agent (Figure 1a, Supplementary
Figure S1a). Further optimization of the ICG-pHLIP manufacturing protocol has been
completed by CordenPharma, and GMP manufacturing is in progress. ICG-pHLIP
reconstituted in PBS was found to be stable in solution for 4 days at room temperature.
The molar attenuation coefficient (i.e. extinction coefficient) of ICG-pHLIP at 810 nm
measured in methanol (Supplementary Figure S2a) was determined as 152,533 M 1cm −1

and used to calculate the concentration of ICG-pHLIP. The absorption and

emission spectra of ICG-pHLIP in DMF (to mimic the hydrophobic environment of
the membrane) are shown in Figure 1b. It is important to note that spectral signals of
ICG-pHLIP do not overlap with the absorption or emission of Methylene Blue and
Isosulfan Blue, dyes which are widely used for tissue staining during surgery and for
histological analysis (Supplementary Figure S2b-f). The interaction of ICG-pHLIP
with membrane lipid bilayers was studied using POPC liposomes. ICG-pHLIP exhibits
pHLIP-like pH-dependent interactions with cell membranes monitored by changes of
the peptide circular dichroism and the fluorescence emission of tryptophan residues
(Figure 1c-e). The midpoint of the transition for ICG-pHLIP insertion in liposomes is
at pH 6.3, meaning 70% of ICG-pHLIP is expected to be inserted across cancer cell
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membranes with a cell surface pH surf of 6.0 at equilibrium, while at the normal cell
surfaces (pH 7.4) only <1% of ICG-pHLIP molecules might insert into membrane.
Since the rate constant of ICG-pHLIP insertion into membrane is high (approximately
5 sec-1) the insertion will occur even under conditions of fast blood flow and limited
exposure time of ICG-pHLIP to acidic cancer cells.

Safety Studies In vitro
The cytotoxicity of ICG-pHLIP was assessed by treatment of human mammary
epithelial cells (HMEpC) with increasing concentrations of ICG-pHLIP (up to 16 µM)
for 72 hours, followed by assessment of cell viability. ICG-pHLIP did not show any
cytotoxic effect at any tested concentration.
ICG-pHLIP interactions with components of the blood were investigated. It was
established that >99.9% of ICG-pHLIP is bound at equilibrium in human, mouse, rat,
minipig, dog and cynomolgus monkey blood, and that the amount of ICG -pHLIP
bound to plasma proteins varies from 95.3% (mouse) to 99.9% (humans)
(Supplementary Table S2). Hemolysis of red blood cells (RBCs) was followed with
increasing concentrations of ICG-pHLIP (up to 1.2 nmol), and lysis was assessed by
the release of hemoglobin. The amount of RBC lysis was less than 2% in all samples.
The rate of ICG-pHLIP hepatic clearance monitored using human, rat, dog, minipig
and cynomolgus monkey hepatocytes was very similar, and varied from 20 -28
µL/min/10 6 cells. The hepatic clearance established in the mouse hepatocytes, which
are larger in size, was higher (42 µl/min/10 6 cells). In general, unbound ICG-pHLIP
(not bound to serum proteins) exhibits a moderate rate of hepatic clearance.
Safety pharmacology profiling of ICG-pHLIP (2 µM) was performed in vitro using 86
enzyme and receptor targets. The most significant inhibitory effect of ICG-pHLIP was
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observed on progesterone B, a nuclear receptor activated by the steroid hormone
progesterone. A subsequent study of ICG-pHLIP’s interaction with progesterone B
was used to establish IC50 and Ki for ICG-pHLIP to be 0.64 µM and 0.51 µM,
respectively (for comparison, the IC50 and Ki for the known R-2050 progesterone
agonist are several fold lower, 0.33 nM and 0.26 nM, respectively, Supplementary
Figure S3). It is unlikely that a significant amount of ICG-pHLIP would reach the
nucleus after a single i.v. administration of the agent, since it binds to cellular
membranes.
The genotoxicity of ICG-pHLIP was evaluated using in vitro bacterial reverse
mutation and mammalian cell micronucleus tests in human peripheral blood
lymphocytes (see details in Supplementary Information). ICG-pHLIP did not show
any evidence of genotoxic activity in these in vitro mutagenicity assays.

Animal Studies
All animal work performed at the University of Rhode Island, the Stryker Corporation,
the Memorial Sloan Kettering Cancer Center (MSKCC) Antitumor Assessment Core
Facility and the Charles River Labs (CRL) was carried out under approved animal
protocols.

Pharmacology
Pharmacokinetic studies were performed on mice and dogs. Bloo d samples were
collected at 5, 15, 30 min and 1, 2, 4, 6, 8, 12 or 16, 24 and 48 h after a single i.v. dose
of ICG-pHLIP (12.3 mg/kg to mice and 0.064 mg/kg to dogs). Evidence of systemic
exposure to ICG-pHLIP was observed in all animals and was quantifiable up to 8-16
hours post administration (Supplementary Table S3). Single exponential decays were
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observed in both cases (Figure 1f, g). The mean clearance (Cl), volume of distribution
(Vz) and elimination half-time (T1/2) values obtained for mice and dogs were very
similar: Cl = 9.53 mL/h/kg (mice) and 11.6 mL/h/kg (dogs); Vz = 53.51 mL/kg (mice)
and 61.6 mL/kg (dogs); and T1/2 = 3.9 h (mice) and 3.7 h (dogs).

Blood Vessel Imaging
Our data show that ICG-pHLIP has a strong affinity to plasma proteins resulting in a
relatively slow blood clearance: the agent remains at significant levels in the blood for
several hours. These are essential features of a good blood pool agent for fluorescence
angiography. Free ICG is currently used as a contrast agent for im aging blood flow,
and it also binds to plasma proteins; however, it is cleared from the blood within a few
minutes, allowing only a limited time window for imaging. We carried out a
comparative study of blood flow imaging using ICG-Cys (ICG-maleimide conjugated
with a Cys residue) and ICG-pHLIP (2.5 nmol of each). As expected, ICG-Cys was
cleared from the blood within the first 5 min (Figure 2a), whereas ICG-pHLIP clearly
revealed the blood vessels for up to 2 hours (Figure 2b and Supplementary Figures
S4). To further investigate the potential utility of ICG-pHLIP in fluorescence
angiography, blood perfusion was imaged in pigs, since the blood circulation of pigs
is closely related to that of humans. The pig received several doses of ICG -pHLIP:
0.052 mg/kg (dose 1) followed by additional 0.12 mg/kg (dose 2) and then followed
by additional 0.24 mg/kg (dose 3). Visualization of ICG-pHLIP NIR fluorescence in
blood vessels was performed using two systems: i) for endoscopic/laparoscopic
imaging inside the pig body cavity (Figure 3a, Supplementary Figure S5a and
Supplementary Video S1), and ii) open field imaging of a pedicle flap (Figure 3b,
Supplementary Figure S5b and Supplement Video S2). Illuminated blood vessels were
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clearly visible at 2 hours post-injection (Supplement Figure S5), establishing the
superiority of ICG-pHLIP use over ICG in fluorescence angiography and other blood
flow/perfusion applications.

Biodistribution and Tumor Targeting
Biodistribution and tumor targeting were followed after a single tail vein injection of
ICG-pHLIP in mice bearing murine and human tumors. Biodistribution studies were
carried out in female and male mice bearing a triple negative 4T1 tumor, which closely
mimics stage IV of human breast cancer. Targeting of 4T1 tumors in BALB/c mice by
ICG-pHLIP is shown in Supplementary Figure S6. To establish the biodistribution of
ICG-pHLIP, animals were euthanized at different time points (5 min, 1, 2, 4, 6, 16, 26
and 48 h), organs were collected and imaged. Representative images of organs are
shown in Figure 4a (values of fluorescence intensity are shown in Supplementary
Table S4 and mean values are given in Supplementary Table S5, the calculated signal
level in each organ at different time points is shown in Supplementary Figure S7). The
kinetics of fluorescence signal changes in organs and tissue is shown in Figure 4b -g.
Organs and tissues were frozen after imaging and processed to measure the signal in
the tissue/organ homogenates. It is challenging to establish precisely the amount of
fluorescent compound in the tissue and organs. However, we made rough estimations
using a calibration curve, which was obtained by spiking known amounts of ICG pHLIP with organs and tissue homogenates collected from control animals. According
to our estimates the amount of ICG-pHLIP within the tumor reaches about 10-15%
ID/g at 4 hours post injection and stays constant up to 24 h, decaying slightly at 48 h.
The clearance was observed to be predominantly hepatic, and the level of the signal
increases in the liver with time and reaches a maximum level at 1-hour post-
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administration, followed by the decay of the signal after 6 hours. Well-perfused organs
like the heart, kidney and lungs were imaged as is (no perfusion with buffer), and it is
evident that a significant amount of the signal (especially at earlier time points) is
coming from the blood associated with these organs, and that the level of the signal
decays with blood clearance. Another group of organs, such as spleen, pancreas,
stomach and brain have a lower signal level, which also decays with blood clearance.
Small and large intestines, bone, skin and muscle (and prostate in male animals, not
shown here) have very low signal levels, estimated to be less than 2% ID/g at all time
points. At 20-48 h, when the blood is cleared and the fluorescence signal in all organs
is minimal, the contrast between tumor and surrounding tissue or healthy organs is
very significant.

ICG-pHLIP tumor targeting was observed in several tumor models of breast (MDA MB-231 human and 4T1 murine), lung (A549 human and LLC murine), epithelial
(melanoma) (M4A4 human), cervical (HeLa human), urinary bladder (UM-UC3
human) and prostate (LNCaP human) cancers. NIR fluorescence imaging on live
animals using the Stryker clinical imaging system was performed at 24 h after a single
i.v. administration of ICG-pHLIP (Supplementary Figure S8). To closely mimic the
conditions of intraoperative imaging, during which fluorescence is monitored from
exposed tissue, the skin was removed from the tumor side while animals were under
anesthesia. Excellent tumor targeting by ICG-pHLIP was seen, and small, medium and
large tumors positioned deep in tissue or exposed at the surface, including small nearby
micro-metastases, were clearly seen (representative images are shown in Figure 5). To
further examine the contrast between tumor and normal tissue, the tumors were
removed with surrounding muscle tissue (Figure 6). The border between tumor and
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muscle in most cases was evidently visible and was defined with high precision by the
fluorescence signal. To correlate the ICG-pHLIP NIRF signal with tumor location, the
tumor-muscle pieces were frozen immediately following NIRF imaging, sectioned,
fixed and stained with hematoxylin and eosin (HE). An excellent correlation between
ICG-pHLIP imaging and HE histopathology in locating the tumors is shown in Figure
7 and Supplementary Figure S9. Fluorescent (non-processed) and HE stained sections
were examined via an IR scanner and optical microscope. Tumors (marked as T) and
surrounding stroma (marked as S1, S2 and S3) exhibit ICG-pHLIP NIR fluorescent
signal, as opposed to the muscles (marked as M1 and M2), which have little signal.
Cancer cells infiltrating into surrounding muscles are clearly seen in magnified ima ges
of stroma. The ability of ICG-pHLIP to stain a tumor mass as well as surrounding
tissues with infiltrating cancer cells is expected to aid improved margin resection
during surgery.

Fluorescence-Guided Tumor Resection
Murine breast cancer 4T1 and human cervical HeLa tumors were implanted into
athymic female nude mice. ICG-pHLIP was given as a single i.v. injection at doses
0.5, 1.25 and 2.5 mg/kg. Surgeries were performed 24 and 48 h after injection under
fluorescence guidance using a Stryker SPY-PHI handheld clinical instrument, which
will be used in breast cancer surgical clinical trials for imaging of ICG-pHLIP. The
images and video obtained during the procedure are shown in Figure 8 and
Supplementary Video S3.

GLP Safety Animal Studies
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The animal efficacy studies indicated that a dose of 0.5 mg/kg of ICG-pHLIP gives
satisfactory imaging, which corresponds to 0.04 mg/kg human dose (h.d.). Toxicology
studies were performed assuming the minimum human dose (h.d.) to be 0.04 mg/kg
(the details of these studies can be found in the Section “Pharmacology and Toxicology
Studies” Supplementary Information). In summary, the following GLP studies were
carried out and no adverse effects were observed:
Single-dose and 7-days repeat i.v. toxicity in beagle dogs: ICG-pHLIP was
administered by single i.v. bolus injection at 0.063 mg/kg (0.85× h.d. recalculated for
dog dose), 1.08 mg/kg (15× h.d.), 2.16 mg/kg (30× h.d.) or once daily for 7 days at
2.16 mg/kg/day (30× h.d. per day) to dogs, and did not adversely affect the overall
health or condition of the animals, any of the measured clinical pathology parameters,
organ weights, macroscopic or microscopic pathology. Based on these results, the no observed-adverse-effect level (NOAEL) was 2.16 mg/kg/day (30× h.d. per day) in
males and females.
7-day repeat i.v. toxicity in B6D2F1 mice: ICG-pHLIP was administered once daily
for 7 days at 4.92 mg/kg/day (1× h.d. per day), 7.38 mg/kg/day (15× h.d. per day) and
12.3 mg/kg/day (25× h.d. per day). The repeat administration of ICG-pHLIP did not
result in any signs of systemic or delayed toxicity in male and female mice.
A cardiovascular telemetry study in unrestrained, conscious non -naïve beagle dogs:
A single administration of ICG-pHLIP at dose levels of 0.072 mg/kg (1× h.d.), 0.36
mg/kg (5× h.d.), and 1.44 mg/kg (20× h.d.) to male dogs resulted in no effect on
systemic blood pressures, heart rate, body temperature, electrocardiographic intervals,
or qualitative ECG parameters up to 24 hours post-dose.
Local tolerance/irritancy in New Zealand white rabbits: A single administration of
ICG-pHLIP at dose levels of 0.124 mg/kg (1× h.d.) and 1.86 mg/kg (15× h.d.) through
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all routes of administration was well tolerated and did not result in any ICG-pHLIP
related changes.
A pharmacological safety assessment on the central nervous system in Sprague
Dawley rats: A single administration of ICG-pHLIP at dose levels of 0.218 mg/kg
(0.88× h.d.), 0.248 mg/kg (1× h.d.), 3.72 mg/kg (15× h.d.) and 7.44 mg/kg (30× h.d.)
had no effect on the central nervous system up to 24 h post-dose.
Micronucleus test in Sprague Dawley rats: A single administration of ICG-pHLIP at
dose levels of 6.25 mg/kg (25× h.d.), 12.5 mg/kg (50× h.d.) and 25 mg/kg (100× h.d.)
showed no evidence of genotoxic activity.

Discussion
The clinical use of ICG fluorescence imaging is growing and has stimulated the
production of a large variety of instruments for open, endoscopic and lap aroscopic
surgical procedures 32. Following intravenous injection, ICG is rapidly bound to plasma
proteins, with minimal leakage into the interstitium. The blood half -life is 2.5 min 33,34.
There are no known metabolites. ICG is rapidly extracted by the liver without
modification and nearly exclusively excreted by the liver, appearing unconjugated in
the bile approximately 8 min after injection, depending on liver vascularization and
function 20. When injected outside blood vessels, ICG binds to proteins and is found in
the lymph, reaching the nearest draining lymph node usually within 15 min, and after
1–2 h, it binds to the regional lymph nodes, deposited into macrophages 35,36. The
intravenous injection dose of ICG typically varies in the range from 0.5 mg/mL/kg to
2.0 mg/mL/kg of body weight. No significant acute toxic effects have been observed
in humans at a high dose of 5 mg/kg of body weight20, and chronic toxicity has not
been reported during many years of clinical experience.
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Even though fluorescence-guidance using ICG allowed improvement of surgical
procedures there remain several important limitations associated with the use of ICG.
ICG (as any non-targeted small molecule including fluorescent dye) has no strong
accumulation within tumors except a weak signal from enhanced permeation retention
(EPR) in vascularized tumors. ICG may be taken up by some cancerous lesions only
if the blood flow uptake is enhanced for the particular lesion. In other cases, ICG has
been used to visualize a lesion via a lack of signal, where the uptake/signal of ICG was
much lower within the lesion compared to the surrounding tissue 37. However, ICG,
does not have any inherent tumor-targeting properties based on selective binding. Also,
the use of ICG for blood-flow visualization is limited by its very fast blood clearance
profile, which requires sometimes multiple injections during the same surgical
procedure. ICG-pHLIP resolves these deficiencies.
Tumor targeting by pHLIP has been well-documented in a large variety of animal
tumor models and human tissues. ICG-pHLIP was used to image cancerous lesions in
human bladders31 and the human upper urinary tract 38. The agent was applied ex vivo
after the surgical removal of organs, followed by washing and NIR fluorescent imagi ng
using clinical imaging instruments. Bladder malignant lesions were targeted by ICGpHLIP, identified by NIR imaging and shown by pathology to have a sensitivity of
97% and specificity of 100%. Carcinoma in situ was accurately diagnosed in 11 cases,
whereas only four of these cases were seen using white light. All malignant upper tract
lesions were targeted by ICG-pHLIP and visualized on NIR imaging with a sensitivity
of 100% (compared to 78.9% white light imaging) and a specificity of 100%. Benign
collecting systems and ureters did not show uptake of the pHLIP construct.
Fluorescent pHLIP peptides were also used in applications to other human tissues for
accurate identification of cancerous lesions 39,40.
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Taken together, the published work on the mechanism of pHLIP ac tion, on tumor
targeting and visualization, as well as in the preclinical studies with the ICG -pHLIP
presented here, including PoC, pharmacology and toxicology assessments, motivate
the clinical translation of ICG-pHLIP for systemic administration for i) real-time blood
flow visualization and ii) targeting and identification of cancerous lesions during
surgical procedures. The agent will be initially evaluated in a first-in-human trial on
breast cancer patients, which will combine advanced pre-operative multiparametric
MRI for the comprehensive assessment of tumor microenvironment including tumor
acidity

with

intra-

and post-operative

NIR

fluorescent imaging,

standard

histopathological and molecular profiling analysis. It is expected that ICG-pHLIP
might allow accurate identification of tumor margins, targeting and visualization of
flat lesions and the identification of micro-metastasis nearby a primary tumor mass,
which are difficult to establish by the naked eye or white light imaging. Further, real
time blood flow imaging with ICG-pHLIP is expected to significantly extend the
imaging time window from several minutes to several hours, allowing imaging to be
performed any time during a surgical procedure after a single injection of the agent.
Potentially, multi-color imaging could be developed: ICG-pHLIP could be used to
visualize blood vessels, and pHLIP with a fluorescent dye emitting in the range of 600 700 nm could be used for tumor imaging, allowing imaging of cancerous lesions and
blood vessels during the same surgical procedure.
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FIgure Legends
Figure 1. Characterization of ICG-pHLIP and blood clearance in mice and dogs.
(a) The Var3 pHLIP sequence is shown with the chemical structure of the ICG dye
coupled to a single Cys residue at the N-terminal part of pHLIP. (b) Normalized
absorbance (black line) and fluorescence (red line) spectra (the excitation is at 805 nm)
of ICG-pHLIP (5 µM) measured in DMF. (c) Circular dichroism (CD) spectra of ICGpHLIP measured in phosphate buffer (pH8) in absence (ICG-pHLIP, pH8 – black line)
and presence (ICG-pHLIP + PC, pH8 – blue line) of POPC liposomes, and in the
presence of POPC liposomes at pH5.2 (ICG-pHLIP + PC, pH5.2 – red line). (d) pHdependent insertion of ICG-pHLIP into the bilayers of POPC liposomes monitored by
changes of the CD spectral signal at 222 nm. The data were fitted with the Henderson Hasselbach equation (red line with 95% confidence interval) to establish the midpoint
of the transition (pK). (e) The kinetics signal (multiplied by -1) of ICG-pHLIP insertion
into lipid bilayers of POPC liposomes as a result of a pH drop from pH8 (blue line in
insert) to pH5 (red line in insert) was monitored in real-time by the tryptophan
fluorescence changes (black line). The gray line is a baseline obtained by mixing ICG pHLIP with POPC liposomes at pH8 with pH8 buffer. The red line is a bi-exponential
fit of the experimental data (85% of the signal changes occur with a rate of 5 sec -1 and
about 15% of final adjustment is completed at a rate of 0.077 sec -1). (f-g) Blood
clearance profile and single exponential fitting curves (red lines) obtained on mice ( f)
and dogs (g) after a single i.v. injection of 12.3 mg/kg of ICG-pHLIP to mice and 0.064
mg/kg of ICG-pHLIP to dogs are shown.
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Figure 2. Imaging of blood vessels in mice. Representative NIR ICG-pHLIP
fluorescent images of blood vessels at different time points after a single i.v. injection
of ICG-Cys (a) or ICG-pHLIP (b).

Figure 3. Imaging of blood vessels in pigs. Representative NIR ICG-pHLIP
(verification batch #1912127) fluorescent images and overlay of fluorescent and color
images of blood vessels at different time points after injection of ICG-pHLIP in PBS
(dose 1 - 0.052 mg/kg; dose 2 - additional 0.12 mg/kg; dose 3 - additional 0.24 mg/kg)
are shown. (a) Imaging inside the pig body cavity was performed using a Stryker 1688
AIM system (808 nm excitation) for endoscopic/laparoscopic imaging (gain 8/10 for
dose 2, gain 7/10 for dose 3). (b) Imaging of a pedicle flap was performed using a
Stryker SPY-PHI handheld device (805 nm excitation) for open field imaging.

Figure 4. Biodistribution

and kinetics. (a) Representative NIR ICG-pHLIP

fluorescent and photo images of tumor, major organs and tissues obtained at different
time points are shown after a single i.v. administration of ICG-pHLIP into BALB/c
female mice bearing murine 4T1 breast tumors in right flanks. Tissues and organs were
imaged immediately after necropsy. The values of the fluorescence signal obtained for
all female mice are presented in Supplementary Tables S4 (the NIR fluorescent sign als
obtained in male mice were similar, data are not shown). (b-g) The calculated mean
and standard deviation values at different time points post-dose are shown. The values
are given in the Supplementary Table S5. The description of %ID/g calculations is
presented in the main text and Methods section.
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Figure 5. Tumor targeting. Representative photos and overlay of photos and in vivo
NIR ICG-pHLIP fluorescent images of athymic female nude mice bearing murine and
human tumors are shown with skin removed f rom the tumor site. The imaging was
performed at 24 hrs after a single i.v. administration of ICG-pHLIP. Arrows indicate
tumor locations.

Figure 6. Ex vivo imaging of tumors with surrounding muscle. Representative
photos, and overlays of photos and ex vivo NIR ICG-pHLIP fluorescent images of
tumors resected with surrounding tissue immediately after in vivo imaging.

Figure 7. Ex vivo imaging and imaging of sections. (a) Representative images of
tumors with surrounding tissue: photos, NIR ICG-pHLIP fluorescent images, overlay
of photos with NIR ICG-pHLIP fluorescent images, and images of HE-stained sections
obtained from the same tumor-muscle pieces are shown. (b) Bright field image of HEstained section and NIR ICG-pHLIP fluorescent images of the adjacent non-processed
section obtained on IR scanner shown in monochrome (green) and 16 -color (white and
red are the highest intensity, and black and dark blue are the lowest intensity)
presentations. T indicates tumor; M indicates muscle, and S indicates stroma. (c)
Magnified bright field images (using 20x objective) of tumor (T), muscle (M1 and
M2), stroma (S1, S2 and S3) of HE-stained section are presented in panel b.

Figure 8. Surgical removal of tumors under fluorescence guidance. Representative
overlay of color and NIR ICG-pHLIP (verification batch #1912127) fluorescent
images (a-e) and NIR fluorescent image (f) recorded using a Stryker SPY-PHI
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handheld device (805 nm excitation) for open field imaging during surgical removal
of tumor.
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METHODS
Manufacturing of ICG-pHLIP
All manufacturing procedures were completed in accordance with good laboratory
practice (GLP) quality control specification. Synthesis of ICG-pHLIP (NH2-Ala-CysAsp-Asp-Gln-Asn-Pro-Trp-Arg-Ala-Tyr-Leu-Asp-Leu -Leu-Phe-Pro-Thr-Asp-ThrLeu-Leu-Leu-Asp-Leu-Leu-Trp-Ala-COOH) acetate salt (C204H283N39O50S2, M.W.
4,145.8 g/mol) was developed and the agent was produced by Iris Biotech, GmbH
(Germany) in partnership with Chemical and Biopharmaceutical Laboratories (CBL)
(Greece). The pHLIP peptide was synthesized on a solid support, followed by
purification using HPLC. ICG-malemide was synthesized in solution, followed by
column purification. ICG-malemide was conjugated with the pHLIP peptide in
solution followed by purification of the final product (ICG-pHLIP) using HPLC.
Seven grams (7 g) of ICG-pHLIP were produced with a purity of 98.7% established
by HPLC (Figures S1a) and identity established by mass-spectrometry (m/z-ratio of
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the synthesized ICG-pHLIP was 1383.0 Da [M+3H] 3+/3 ± 1 and the expected
theoretical mass is 1382.9 Da [M+3H] 3+/3) was used in proof of concept (PoC),
toxicology and pharmacokinetics studies. Manufacturing of ICG-pHLIP and analytical
characterization were further optimized by CordenPharma, GmbH (Germany).
TheHPLC analytical method developed for the detection of ICG-pHLIP is the
following: HPLC column is Waters, BEH C8, 150 x 2.1 mm, 1.7 µm particle size;
temperature is 33°C; injection volume is 1.2 µL; eluent A is water + 0.04% TFA; eluent
B is CH3CN + 0.04% TFA; flow rate is 0.4 mL/min; detection wavelength is 220 nm;
and the following gradient:

Time,

Eluent B,

min

%

0

30

0.63

30

3.63

50

14.88

73

15.03

95

20.13

95

20.14

30

27.63

30

A spiking experiment was used to compare the ICG-pHLIP product obtained after
optimization of the manufacturing process with previously produced material. Both
ICG-pHLIP products were mixed in a ratio of 1:1 and analyzed by HPLC (Figure S1b).
The presence of a single signal on the HPLC chromatogram confirms the identity of
ICG-pHLIP products. An m/z-determination of the material produced was performed
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by UHPLC-MS. The analysis provided a m/z-ratio of 1381.96 Da [M+3H] 3+/3 (Figure
S1c). GLP ICG-pHLIP verification batch #1912127 was manufactured in Frankfurt by
CordenPharma, the acceptance criteria are presented in Supplementary Table S1.

Stability Study
Stability studies were performed with ICG-pHLIP formulations in PBS and PBS
containing 5% DMSO or 5% Ethanol (vol/vol). The tumor targeting capability in mice
is independent of formulation. Formulation of ICG-pHLIP in PBS/5% Ethanol was
used in PoC animal studies, and in toxicity studies on mice, rats and dogs. For the
PBS/5%DMSO formulation 1 mg of the lyophilized powder of ICG-pHLIP was
dissolved in 75 µl of DMSO (to make 3.2 mM solution), then 10 µl of 3.2 mM stock
was mixed with 190 µl PBS to make a 0.16 mM solution of ICG-pHLIP (5% DMSO).
For the PBS/5%Ethanol formulation, the lyophilized powder of ICG-pHLIP was
dissolved at concentration of 1.6 mg/ml in PBS/5% Ethanol solution. Finally, the
formulation selected for human use the was prepared by dissolving the lyophilized
powder of ICG-pHLIP at a concentration of 0.8 mg/ml in PBS. All formulations were
kept at room temperature and protected from light. The aliquots were taken at 0.5 or
1, 3, 6, 24, 48 and 72 hours (102 hrs for ICG-pHLIP dissolved in PBS) for analytical
HPLC analysis using a Zorbax SB-C18 column (4.6 x 250 mm, 5 µm) with a binary
solvent system using a 15-85% water and acetonitrile gradient with 0.05% TFA over
25 min. All formulations demonstrated stability (>95% purity) up to 72 hours when
kept at room temperature. Formulation of ICG-pHLIP in PBS was stable in solution
for 4 days kept at RT.
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Liposome Preparation
POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, Avanti Polar Lipids, Inc.)
liposomes were used in biophysical measurements to mimic cells, and to investigate
ICG-pHLIP interaction with lipid bilayers. Large unilamellar vesicles (LUVs) were
prepared by extrusion. POPC dissolved in chloroform was desolvated in a rotary
evaporator and placed under high vacuum for 2 hours to create a phospholipid film.
Lipids were then rehydrated in phosphate buffer (pH8) and repeatedly extruded
through membranes with a pore size of 100 nm to make LUVs.

Absorbtion and Emission Measurements
Absorbtion spectra of ICG-pHLIP, Methylene Blue (MB) and Isosulfan Blue (IB) in
PBS, methanol, DMSO or DMF were measured in a cuvette with 1 cm path length
using a Genesys 10S UV-Vis (Thermo Scientific) spectrophotometer. Fluorescence
spectra of ICG-pHLIP (with an excitation of 295 nm to record tryptophan fluorescence
of pHLIP, and 805 nm to record ICG fluorescence), MB (with an excitation of 670
nm) and IB (with an excitation of 630 nm, the fluorescence was insignificant) were
measured in aqueous solution (in the presence or absence of POPC liposomes in the
case of ICG-pHLIP), methanol, DMSO or DMF using PC1 (ISS, Inc) and SpectraMax
M2 (Molecular Devices) spectrofluorometers.

Calculation of Molar Attenuation Coefficient
Different amounts of ICG-pHLIP (1.85, 1.808, 3.90, 4.15, 4.191, 7.16 and 7.19 mg)
were weighed and dissolved in 2 ml of methanol followed by 25x or 50x further
dilution in methanol for measurements of absorbance spectra (each spectra were
recorded several times). The absorbance spectra were recorded from 700 to 900 nm. It
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was ensured that the absorbance was zero at 900 nm. All spectra were normalized and
adjusted for the peptide content in the sample. The OD reading at 810 nm was used to
calculate the molar attenuation coefficient according to the equation:
𝜀810 =

𝑂𝐷 810
𝑐 ∙𝑙

where c is the concentration of ICG-pHLIP calculated by weight and l is the optical
path of the cuvette (1 cm). The mean molar attenuation coefficient for ICG-pHLIP in
methanol at 810 nm was established to be 152,533 ± 5,225 M -1 cm-1.

Circular Dichroism and pH-Dependence
Circular dichroism (CD) measurements were employed to monitor the pH-dependent
insertion of ICG-pHLIP into the membrane of POPC liposomes and the formation of
helical structure. CD measurements were performed using a MOS-450 spectrometer
(Biologic, Inc) with its temperature control set to 25.0°C. CD spectra were recorded
from 200 to 260 nm with steps of 1 nm. The pH-dependent insertion of ICG-pHLIP
into the lipid bilayer of POPC liposomes was studied by monitoring the changes in the
molar ellipticity (measured in millidegrees) at 222 nm as a function of pH. After the
addition of aliquots of citric acid, the pHs of solutions containing 5 μM ICG-pHLIP
and 750 µM POPC liposomes were measured using an Orion PerHecT ROSS
Combination pH Micro Electrode and an Orion Dual Star pH and ISE Benchtop Meter
before and after each spectrum measurement to ensure that equilibrium is achieved.
The ellipticity millidegrees were plotted as a function of pH. The pH-dependence was
fit with the Henderson-Hasselbalch equation (using OriginLab software) to determine
the cooperativity (𝑛) and the mid-point (𝑝𝐾 ) of a transition:
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑝𝐻 𝑑𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑐𝑒 =

1
1+

10 𝑛(𝑝𝐻−𝑝𝐾)
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Kinetics Measurements
To follow ICG-pHLIP insertion into the lipid bilayer of POPC liposomes in real-time,
kinetics measurements were performed using a SFM-300 mixing system (Bio-Logic
Science Instruments) in combination with a MOS-450 spectrometer with its
temperature control set to 25.0°C. ICG-pHLIP pre-mixed with POPC liposomes at
phosphate buffer at pH8 were mixed (dead time is 5 ms) with acid to drop the pH from
pH8 to pH5 and promote pHLIP insertion into the bilayers. The insertion process was
monitored by recording changes of the tryptophan fluorescence of pHLIP excited at
295 nm and using a cut off filter at 320 nm.

Cytotoxicity
Human mammary epithelial cells (HMEpC) acquired from Cell Applications, Inc.
were authenticated and stored according to supplier’s instructions. Cells were cultured
in mammary epithelial cell growth medium provided by manufacturer. HMEpC cells
were loaded in the wells of 96-well plates (~6,000 cells per well) and incubated
overnight. Increasing amounts of ICG-pHLIP dissolved in cell growth medium were
added to cells to give the following final concentrations of ICG-pHLIP with cells:
0.125, 0.25, 0.5, 1, 2, 4, 8 and 16 μM. After 48 and 72 hours of incubation, a
colorimetric reagent (CellTiter 96 AQ ueous One Solution Assay, Promega) was added
for 2 hours followed by measuring absorbance at 490 nm to assess cell viability. All
samples were prepared in triplicate and each experiment was repeated several times.
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Whole Blood and Plasma Binding Assays
Whole blood and plasma binding assays were performed by Cyptotex US, LLC using
human, mouse, rat, minipig, dog and cynomolgus monkey blood samples. ICG-pHLIP
or ICG (5 µM) was added to whole blood or plasma or PBS and dialyzed in a rapid
equilibrium dialysis device (with 8 kDa cut off) against PBS. Both fractions were
processed and analyzed. Solution of water/NaCl/ascorbic acid (100/37/0.5 v/w/w) and
ACN/MeOH (50/50 v/v) were used to precipitate proteins, followed by evaporation of
the eluent, dry and reconstitution of samples for LC-MS/MS analysis on SCIEX 6500
QTRAP mass spectrometer. The data are presented in Table S2.

pHLIPIS : NH2-A^(Cam)DDQNPWR^AYLDL^L^FPTDTLLLDLL^WA-COOH

where A^ is Alanine(13C3,15N); L^ is Leucine(13C6,15N); R^ is Arginine(13C6,

15N4);

Cam is Cysteine-carbamidomethylation, synthesized and purified by New England
Peptides, Inc was used as internal standard (IS).

Hepatocyte Stability Assay
Hepatocyte stability (clearance) assays were performed by Cyptotex US, LLC using
human, mouse, rat, minipig, dog and cynomolgus monkey poo led cryopreserved
hepatocytes. ICG-pHLIP was incubated with hepatocytes at 37°C for different period
of times: 0, 10, 20, 40 and 60 min (for mouse hepatocytes) and at 0, 15, 30, 60 and 120
min (for human, mini pig, rat, dog and cynomolgus monkey hepatocyte s). Hepatocytes
(100 µL of concentration 0.5x10 6 cells cells/mL) and stock solvent (PBS/EtOH, 95/5
v/v) spiked with 1 µM ICG-pHLIP along with unspiked hepatocytes and stock solvent
were placed in 0.5 mL plate. Solution of water/NaCl/ascorbic acid (100/37/0 .5 v/w/w)
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and ACN/MeOH (50/50 v/v) were used to precipitate proteins, followed by
evaporation of the eluent, dry and reconstitution of samples for LC-MS/MS analysis.
The data were calculated as % parent remaining by assuming zero minute time point
peak area ratio (analyte/ pHLIPIS) as 100% and dividing the remaining time point peak
area ratios by zero minute time point peak area ratio. Data were fitted to a first-order
decay model to determine the half -life. From the logarithmic plot of peak area against
time, the slope was determined, where the (-slope) equals the elimination rate constant
(𝑘). The half-life (𝑡1/2 ) equals 0.693/ 𝑘 and the intrinsic clearance (𝐶𝑙 𝑖𝑛𝑡) (ml/min/10 6
cells) was calculated using the equation:

𝐶𝑙 𝑖𝑛𝑡 =

0.693𝑉
𝑡1/2

where 𝑉 equals the ratio of the incubation volume (ml) to the number of cells.

Hemolysis assay
Single donor human whole blood was purchased from Innovative Research, Inc. Red
blood cells (RBCs) were collected by centrifugation of whole blood at 2000 rpm for
10 minutes followed by washing three times with Dulbecco’s PBS (DPBS) and re suspended in DPBS at a concentration of 7.5% (vol:vol). Varying concentrations of
ICG-pHLIP (0.075, 0.15, 0.3, 0.6, 1.2 nmol) in DPBS were added to RBCs to give a
5% RBC suspension (the total volume of the solution with RBC was 150 µL). The
resultant mixtures were incubated at 37°C for 2 hours and then centrifuged at 1500
RCF (~3000 RMP) for 10 min. Hemolysis was assessed by the release of hemoglobin,
which was monitored by measuring absorbance at 450 nm of the supernatant
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hemoglobin. DPBS was used as a negative control. As positive controls, which result
in 100% lysis of RBCs, we used i) water and ii) 10% of Triton X-100. The percentage
of hemolysis was calculated as follows:
% 𝐻𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠 = 100 ∙

𝑂𝐷 𝑇𝑒𝑠𝑡 − 𝑂𝐷𝑁𝐶
𝑂𝐷𝑃𝐶 − 𝑂𝐷𝑁𝐶

where, ODTest, ODNC, and ODPC are the optical density reading (absorbance) values of
the test sample, negative control and positive control, respectively. The assay was
performed in triplicate. The amount of RBC lysis was less than 2% in all samples. For
reference, in a mouse study 2.5 nmol of ICG-pHLIP is injected per mouse (a 20-25 g
mouse has about 1.2 mL of blood), or 2.08 nmol/ml (the dose in humans is much
lower), while in a hemolysis assay the maximum tested concentration was 8 nmol/ml.

Enzyme Binding Assay
The ICG-pHLIP enzyme binding assays were performed by Eurofins Panlabs, Inc.
according to standard assay protocols. The following enzymes were used in the binding
assay with 2 µM of ICG-pHLIP: acetyl cholinesterase; peptidase (angiotensin
converting enzyme); ATPase (Na +/K+, pig heart); CTSG peptidase (cathepsin G);
cyclooxygenases COX-1 and COX-2; monoamine oxidases MAO-A and MAO-B;
phosphodiesterases PDE3 and PDE4D2; protein tyrosine kin ase (insulin receptor);
protein tyrosine kinase (LCK); protein serine/threonine kinase (PKC, non -selective);
adenosine A1 and A2A; adenosine transporter; adrenergic α1A, α1B, α1D, α2A, α2B,
β1 and β2; norepinephrine transporter (NET); androgen (testostero ne); angiotensin
AT1; bradykinin B2; calcium channels L-type (benzothiazepine, dihydropyridine,
phenylalkylamine); calcium channel N-type; cannabinoid CB1 and CB2; chemokine
CCR1; cholecystokinin CCK1 (CCKA) and CCK2 (CCKB); dopamine D1, D2L and
D2S; dopamine transporter (DAT); endothelin ETA; estrogen ERα; GABA
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transporter; GABAAs (flunitrazepam, central; Ro-15-1788, hippocampus and chloride
channel, TBOB); glucocorticoid; glutamate (AMPA, kainate, agonism NMDA,
glycine

NMDA,

phencyclidine

NMDA,

polyamine

NMDA,

and

mGlu5

metabotropic); glycine (strychnine-sensitive); histamine H1 and H2; chemokine
CXCR2 (IL-8RB); cysteinyl leukotriene (CysLT1); melanocortin MC1 and MC4;
muscarinic M1, M2, M3, and M4; tachykinin NK1; neuropeptide Y Y1; nicotinic
acetylcholine α1 (bungarotoxin) and α3β4; opiate δ1 (OP1, DOP), κ (OP2, KOP), and
μ (OP3, MOP); platelet activating factor (PAF); potassium channels (KATP and
hERG); PPARγ; serotonin (5-hydroxytryptamine) 5-HT1A, 5-HT1B, 5-HT2A, 5HT2B, 5-HT2C, and 5-HT3; serotonin transporter (SERT); sodium channel (site 2);
vasopressin V1A; progesterone (PR-B). The most significant inhibitory effect of ICGpHLIP was observed on progesterone B and was followed by an additional study to
identify IC50 values, which were determined by a non-linear least square regression
analysis using MathIQTM (ID Business Solutions Ltd., UK). The Ki values were
calculated by the equation from Cheng and Prusoff [Cheng, Y., Prusoff, W.H.,
Biochem. Pharmacol. 22:3099-3108, 1973] using the observed IC50 of ICG-pHLIP,
the concentration of radioligand employed in the assay, and the historical values for
the KD of the ligand (Eurofins Panlabs data). The Hill coefficient (n H), defining the
slope of the competitive binding curve, was calculated using MathIQTM. The IC50, Ki,
and n H values were established for ICG-pHLIP and compared to the known
progesterone agonist, R-2050 (Figure S3).

Pharmacology and Toxicology Studies
Pharmacology and toxicology studies were performed at the Memorial Sloan Kettering
Cancer Center (MSKCC) Antitumor Assessment Core Facility and at Charles River
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Labs (CRL) under approved animal protocols. The minimum human dose (h.d.) of
ICG-pHLIP is 0.04 mg/kg. All doses of ICG-pHLIP used in pharmacology and
toxicology studies were calculated based on the minimum h.d.
Pharmacokinetics of ICG-pHLIP in the Beagle dogs following a single i.v. bolus
injection
The objective of this study performed at CRL was to characterize the pharmacokinetic
profile of ICG-pHLIP in the Beagle dogs following a single i.v. injection.
The study design was as follows:
Targeted

Achieved

Dose

Achieved

Group Test
No.

Dose
No.

Dose Level Dose Level a Volume

Concentration

(mg/kg)

(mg/kg)

(mL/kg)

(mg/mL)

0.072

0.064

2.5

0.025

Material

of

Males

ICG
1

3

pHLIP
a

achieved dose levels calculated based on 87.7% mean recovery results from

formulation analysis.
Blood samples were collected at 5, 15, and 30 minutes, and 1, 2, 4, 6, 8, 12, 24, and 48
hours post-dose for pharmacokinetic evaluation. Samples were placed on crushed wet
ice until centrifugation, which was carried immediately. The samples were centrifuged
as per standard procedures. An aliquot of 250 µL of the resultant plasma was separated,
transferred to 2.0 mL low-bind tubes containing 1.25 mL of methanol, mixed and
frozen immediately over dry ice and transferred to a freezer at -80°C. At the time of
analysis, samples were thawed, extracted, and analyzed via LC-MS/MS according to
the validated protocol using pHLIPIS.
In conclusion, the administration of a single dose of ICG-pHLIP by i.v. bolus injection
was well-tolerated in dogs at a dose level of 0.064 mg/kg.
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Evidence of systemic

exposure to ICG-pHLIP was observed in all animals and was quantifiable up to 8 or
12 hours post-dose. The mean C0 (theoretical concentration at time zero following a
bolus dose administration), AUC 0-48hr (area under the concentration-time curve from
time zero to 48hrs) and AUC INF (area under the concentration-time curve from time
zero extrapolated to infinity) values were 1410 ng/mL, 5450 hr*ng/mL, and 5550
hr*ng/mL, respectively.

Pharmacokinetic testing of ICG-pHLIP in mice
The purpose of this study, performed at MSKCC,

was to determine the

pharmacokinetic parameters of ICG-pHLIP in 3 female B6D2F1 mice following a
single i.v. injection of ICG-pHLIP at a dose of 12.3 mg/kg. Blood was collected in
EDTA tubes at 5, 15, 30 minutes, and 1, 2, 4, 6, 8, 16, and 24 hours post-injection,
,followed by centrifugation to separate the plasma, and flash frozen. At time of
analysis, samples were thawed, extracted, and analyzed via LC-MS as per the validated
protocol using pHLIPIS .
In conclusion, administration of a single dose of ICG-pHLIP by i.v. bolus injection
was well tolerated in mice at a dose level of 12.3 mg/kg.

Evidence of systemic

exposure to ICG-pHLIP was observed in all animals and was quantifiable up to 16
hours post-dose.

Single i.v. toxicity with acute (24 hrs) and delayed (14 days) necropsy and TK in
Beagle dogs;
7-days repeat i.v. toxicity in dog with acute (24h after last injection) and TK on days
1 and 7 in Beagle dogs
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The objectives of this GLP study, performed at CRL, were to determine the potential
toxicity of ICG-pHLIP, when given by single dose i.v. injection or once daily (i.v.
injections) for 7 days in dogs, and to evaluate the potential reversibility of any findings
following the single dose injection. In addition, toxicokinetic characteristics of ICG pHLIP were examined.

The study design was as follows (40 Beagle dogs: 20 male and 20 female):
No. of Animals
Dose
Dose Level
Grou Test

Dose
Volume

(mg/kg/day
p No. Material

Recovery
Main Study

Concentratio

Study

(mL/kg
)

n (mg/mL)

Male Female Male Female

)
s

s

s

s

Vehicle
1

0

2.5

0

3

3

2

2

0.072 **

2.5

0.029

3

3

-

-

1.08 ***

2.5

0.432

3

3

-

-

2.16 ****

2.5

0.864

3

3

2

2

2.5

0

2

2

-

-

2.5

0.864

2

2

-

-

*

ICG2
pHLIP
ICG3
pHLIP
ICG4
pHLIP
5

Vehicle 0
ICG-

6

2.16
pHLIP

*

5% (vol/vol) EtOH in PBS, pH 7.4
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**

based on dose formulation analytical results, animals from Group 2 received a

dose level of 0.063 mg/kg, which is equivalent to 0.875x h.d.
***

equivalent to 15x h.d.

****

equivalent to 30x h.d.

The following parameters and end points were evaluated in the study: mortality,
clinical observations, body weights,
electrocardiology

assessments,

food consumption, ophthalmology and

clinical

pathology

parameters

(hematology,

coagulation, clinical chemistry, and urinalysis), toxicokinetic parameters, gross
necropsy findings, organ weights, and histopathological examinations.
There were no unscheduled deaths.

There were no ICG-pHLIP-related clinical

observations, and no ICG-pHLIP-related effects on the assessment of body weights,
food consumption, ophthalmology and electrocardiology changes, hematology,
coagulation, and urinalysis parameters, organ weights, or macroscopic and
microscopic evaluations at any dose level tested following a single dose or a daily 7day repeat dose administration.
Administration of ICG-pHLIP to dogs when given by repeated i.v. injection at
2.16 mg/kg/day for 7 days resulted in non-adverse clinical chemistry changes limited
to minimal decreases in cholesterol in both males and females.
Systemic exposure to ICG pHLIP appeared to be independent of sex. Following a
single i.v. bolus administration of ICG-pHLIP, mean C0 and AUCTlast values increased
with increasing dose in an approximately dose proportional manner from 1.08 to 2.16
mg/kg. Following daily i.v. bolus administration of 2.16 mg/kg ICG-pHLIP, mean C0
and AUCTlast values were 38,400 ng/mL and 65,400 hr*ng/mL, respectively, on Day 1
and were 42,700 ng/mL and 72,300 hr*ng/mL, respectively, on Day 7. Systemic
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exposure (AUCTlast) to ICG-pHLIP did not appear to increase following repeated IV
bolus administration of 2.16 mg/kg ICG-pHLIP.
In conclusion, ICG-pHLIP administered by a single i.v. bolus injection at 0.063,
1.08, or 2.16 mg/kg or once daily for 7 days at 2.16 mg/kg/day to dogs did not
adversely affect overall health or condition of the animals, and had no impact on
clinical pathology parameters, organ weights, macroscopic or microscopic pathology.
Decreases in cholesterol levels were noted in ICG-pHLIP-treated animals at 2.16
mg/kg/day after repeated dosing but were considered non -adverse. Based on these
results, the no-observed-adverse-effect level (NOAEL) was considered to be
2.16 mg/kg/day, with a Day 1 mean C max of 40,300 ng/ml and AUC0-24 of
322,000 hr*ng/ml in males and females combined.

7-day repeat i.v. toxicity in mice with acute (24 hrs after last injection) and delayed
(14 days) necropsy and TK on days 1 and 7 in B6D2F1 mice
The purpose of this GLP study performed at MSKCC was to assess the acute and
delayed toxicity of a repeat administration of ICG-pHLIP in mice. The ICG-pHLIP
was administered for 7 consecutive days.
The study design was as follows (82 B6D2F1 mice: 41 male and 41 female):
Group

Test

Dose Level

No.

No.

Material

(mg/kg/day)

mice/group

Sex

Sacrifice

Necropsy

Day 8

Yes

Interim sacrifice on Days 8 and 9
1

Vehicle*

0

2

ICG-

13.6 **

10

10
pHLIP
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Male

Female

3

Vehicle

0

4

ICG-

13.6

10

Male

10

Female

5

Male

5

Female

Day 9

pHLIP
Final sacrifice on Days 21 and 22
5

Vehicle

0

6

ICG-

13.6

Day 21

pHLIP
Yes
7

Vehicle

0

8

ICG-

13.6

5

Male

5

Female

3

Male

3

Female

Day 22

pHLIP
TK samples
9

Vehicle

0

10

ICG-

13.6

Day 7

pHLIP
No
11

Vehicle

0

12

ICG-

13.6

3

Male

3

Female

Day 8

pHLIP
*

5% (vol/vol) EtOH in PBS, pH 7.4

**

equivalent to 27.6x h.d.

Throughout the study, body weights, clinical signs, clinical pathology (hematology
and clinical chemistry), and histopathology were collected.
In conclusion, the repeat administration of ICG-pHLIP may be associated with germ
cell degeneration in males with incidence and severity decreasing over time. No other
signs of systemic or delayed toxicity were observed.
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Follow up 7-days repeat i.v. toxicity in male mice with acute (24 hrs after last
injection) and delayed (14 days) necropsy and TK on days 1 and 7 in B6D2F1 mice
The purpose of this GLP study performed at MSKCC was to assess the acute and
delayed toxicity on the male reproductive system of mice of a repeat administration of
ICG-pHLIP at different concentrations. The ICG-pHLIP was administered once/day
for 7 consecutive days.
The study design was as follows (77 male B6D2F1 mice):
No.

of

Dose Level
Grou

Test

p No.

Material

Male

Sacrifi

Necrop

mice/grou

ce

sy

Day 8

Yes

Day 21

Yes

(mg/kg/day
)
p
Interim sacrifice on Day 8
1

Vehicle*

0

2

ICG-

4.92 **

10

10
pHLIP
3

ICG-

7.38 ***
10

pHLIP
4

ICG-

12.3 ****
10

pHLIP
Final sacrifice on Day 21
5

Vehicle

0

6

ICG-

4.92

5

5
pHLIP
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7

ICG-

7.38
5

pHLIP
8

ICG-

12.3
5

pHLIP
TK samples
9

Vehicle

0

10

ICG-

4.92

3

3
pHLIP
11

ICG-

7.38

Day 7

No

3
pHLIP
12

ICG-

12.3
3

pHLIP
*

5% (vol/vol) EtOH in PBS, pH 7.4

**

equivalent to 10x h.d.

***

equivalent to 15x h.d.

****

equivalent to 25x h.d.

Throughout the study, body weights, clinical signs, and histopathology were collected.
In conclusion, the repeat administration of ICG-pHLIP at all dose levels is well
tolerated, with no indication of germ cell degeneration or other toxicity to the male
reproductive system.

Local tolerance/irritancy in New Zealand white rabbits
The objective of this GLP study performed at CRL was to compare the i.v., intraarterial, perivascular and subcutaneous routes for potential irritation following a single
injection of ICG-pHLIP in the rabbits.
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The study design was as follows (18 male New Zealand white rabbits):
Dose

Dose

per

Volume

Total

Targete
Grou

Test

d

Dose

injected

Dose

No. of
3kg

(mL/kg)

Conc.

Dose Based

p No. Material Level

Males
Rabbit i.v.

right (mg/mL) on

3kg

(mg/kg)
(mg)

ear vein

Rabbit (mg)

0

0

3

0

0

3

0.124 **

0.372

3

0.041

0.372

3

1.86 ***

5.58

3

0.62

5.58

3

Vehicle
1
*

ICG2
pHLIP
ICG3
pHLIP
S
u
b
c
.
i.a. left ear
l
artery/
e
Subc.lumba
f
r
t
p
e
r
i
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Dose

Dose

Total

per

Volume

Targete
Grou

Test

d

Dose

injected

Dose

No. of
3kg

(mL/kg)

Conc.

Dose Based

p No. Material Level

Males
Rabbit i.v.

right (mg/mL) on

3kg

(mg/kg)
(mg)

ear vein

Rabbit (mg)
v
e
n
o
u
s
s
p
a
c
e
0
.

4

Vehicle

0

0

1.5/1.5

0
2

0

3

0.379

3

5
0
ICG5

.
0.124

0.372

1.5/1.5

pHLIP

0.041
2
5
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Dose

Dose

Total

per

Volume

Targete
Grou

Test

d

Dose

injected

Dose

No. of
3kg

(mL/kg)

Conc.

Dose Based

p No. Material Level

Males
Rabbit i.v.

right (mg/mL) on

3kg

(mg/kg)
(mg)

ear vein

Rabbit (mg)
0

ICG6

.
1.86

5.58

1.5/1.5

pHLIP

0.62
2

5.735

3

5
i.a. = intra-arterial; i.v. = intravenous; subc. = subcutaneous.
*

5% (vol/vol) EtOH in PBS, pH 7.4

**

equivalent to 1x h.d.; based on dose formulation analytical results, animals from

Group 2 and 5 received a dose level of 0.109 mg/kg for i.v.,i.a. and/or subc. injection
and 0.009 mg for perivenous space injection.
***

equivalent to 15x h.d.

The following parameters and end points were evaluated in this study: clinical signs,
local irritation

assessment, body weights

(for dose calculation only), and

histopathology of the injection sites. There were no clinical signs, local irritation or
any microscopic changes associated with ICG-pHLIP during the study.
In conclusion, a single administration of ICG-pHLIP via i.v., intra-arterial, perivenous
and subcutaneous injection was well tolerated in rabbits at total dose levels of 0.124
and 1.86 mg/kg. Administration did not result in any ICG-pHLIP-related changes.
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A pharmacological safety assessment on the central nervous system of the Sprague
Dawley rats
The objective of this GLP study performed at CRL was to evaluate the
pharmacological effects of ICG-pHLIP on the central nervous system following a
single i.v. bolus injection in rats.
The study design was as follows (32 male Sprague Dawley rats):
Dose

Dose

Dose

Level

Volume

Concentration

(mg/kg)

(mL/kg)

(mg/mL)

0

5

0

8

0.218 **

5

0.0436

4

0.248 ***

5

0.0496

4

3.72 ****

5

0.744

8

7.44 *****

5

1.488

8

Group Test
No.

1

No.

Material

Vehicle*

of

Males

ICG2a
pHLIP
ICG2b
pHLIP
ICG3
pHLIP
ICG4
pHLIP
*

5% (vol/vol) EtOH in PBS, pH 7.4

**

equivalent to 0.88x h.d.

***

equivalent to 1x h.d.

****

equivalent to 15x h.d.

*****

equivalent to 30x h.d.

Functional observation battery (FOB) tests were performed once prior to dosing and
again at 5 minutes, 3 and 24 hours post-dose and included the following assessments:
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palpebral closure, eye prominence, pupil size, pupillary response, lacrimation,
salivation, body tone, extensor thrust, pinna reflex, tactile reflex, overall animal
reactivity, auricular startle, air righting reflex, body temperature (rectal). Additional
evaluations consisted of mortality and clinical observations.
There were no ICG-pHLIP -related changes on any qualitative or quantitative FOB
parameters at 0.218, 0.248, 3.72 and 7.44 mg/kg up to 24 hours post-dose.
In conclusion, a single i.v. bolus administration of ICG-pHLIP at dose levels of 0.218,
0.248, 3.72 and 7.44 mg/kg to rats had no effect on the central nervous system up to
24 hours post-dose.

A cardiovascular telemetry study in unrestrained conscious non-naïve Beagle dogs
The objective of this GLP study performed at CRL was to evaluate the potential
cardiovascular effects of ICG-pHLIP in instrumented dogs when administered by i.v.
bolus injection using a Latin square design.
Each of the four male dogs received a dose of Reference Item (5 % Ethanol in
Phosphate buffered saline (PBS), pH of 7.4 ± 0.2) and three dose levels of ICG-pHLIP
(0.072, 0.36, and 1.44 mg/kg), with a 7-day washout period between each dose. The
dose was administered by i.v. bolus injection at a dose volume of 2.5 mL/kg.
The study design was as follows (16 male Beagle dogs):
Dosing Schedule (mg/kg)
Animal

Dose 1

Dose 2

Dose 3

Dose 4

1

0

0.072

1.44

0.36

2

0.072 *

0.36

0

1.44

3

0.36 **

1.44

0.072

0

No.
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1.44 ***

4

Dose

0

0.36

Level Concentration

Dose

0.072

Volume No.

(mg/kg)

(mg/mL)

(mL/kg)

Males

0

0

2.5

4

0.072

0.029

2.5

4

0.36

0.144

2.5

4

1.44

0.576

2.5

4

*

equivalent to 1x h.d.

**

equivalent to 5x h.d.

***

equivalent to 20x h.d.

of

The following cardiovascular parameters were evaluated for all animals from 2 hours
prior and up to 24 hours post each dose: systemic blood pressures (systolic, diastolic,
mean

arterial,

and

pulse

pressure),

heart

rate,

body

temperature,

electrocardiographic duration/intervals (PR, QRS, QT, and QTc).

and

Qualitative

evaluation of the electrocardiographic waveforms was performed twice prior to each
dose (at least 30 minutes apart) and at 5, 15, and 30 minutes, 1, 2, 3, 4, 6, 12, and 24
hours post-dose. Additional evaluations consisted of mortality

and clinical

observations. There were no mortalities or ICG-pHLIP-related

clinical signs

throughout the course of the study.
In conclusion, a single i.v. bolus injection of ICG-pHLIP at 0.072, 0.36, and
1.44 mg/kg to male dogs resulted in no effect on systemic blood pressures, heart rate,
body temperature, electrocardiographic intervals (PR, QRS, QT or heart rate corrected
QT [QTc]), or qualitative ECG parameters up to 24 hours post-dose.
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Micronucleus test in Sprague Dawley rats
The objective of this GLP study performed at CRL was to determine the potential
genotoxicity of ICG-pHLIP when given by i.v. bolus injection to rats using the
peripheral blood micronucleus test.
In order to determine the maximum tolerated dose, a dose-range finding test was
performed prior to the main test, where male and female rats (3 animals/sex) were
administered a single dose of ICG-pHLIP by i.v. injection. The doses evaluated were
14 mg/kg and 25 mg/kg using 5% EtOH in PBS, pH 7.4 as the vehicle. Animals were
observed for signs of toxicity and/or mortality. As no adverse clinical signs were noted
during the dose-range finding test, the maximum practical dose of 25 mg/kg was set
as the high dose to be evaluated in the main test using a single sex (males).
The main phase study design was as follows (37 rats: 31 males and 6 females):
Dose
Group
Test Material
No.

No. of Animals

Dose Level Dose Volume
Concentration
(mg/kg)

(mL/kg)

Male

Female

3
3
5
5
55
5
55

3
3
-

(mg/mL)
1
2
3
4
5
6
7
*

ICG-pHLIP
14 ***
ICG-pHLIP
25 ****
NP*****
ICG-pHLIP 6.25 *
ICG-pHLIP 12.5 **
ICG-pHLIP 25
CP******
10
equivalent to 25x h.d.

10
10
10
10
10
10
10

1.4
2.5
0
0.625
1.25
2.5
1

**

equivalent to 50x h.d.

***

equivalent to 56x h.d.

****

equivalent to 100x h.d. – the maximum practical dose of ICG-pHLIP

*****

NC is the negative control, 5% EtOH in PBS, pH 7.4.

******

PC is the positive control, cyclophosphamide monohydrate. Animals were

dosed twice with CP by oral gavage with an interval of 24 hours (± 15 minutes).
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Analysis of ICG-pHLIP dosing formulations conducted during the study confirmed
that all formulations were acceptable for use.
No mortalities occurred during the main test and no ICG-pHLIP-related adverse
clinical signs were observed. Additionally, no ICG-pHLIP-related body weight loss
or depression in body weight gains were observed.
Blood was collected for micronuclei evaluation at 45 hours post-dose (Groups 3 to 7),
and 69 hours post-dose (Groups 3 and 7). The proportion of immature erythrocytes
among total erythrocytes in the peripheral blood (%RETs) and the percentage of
micronucleated reticulocytes (%MN-RETs) in the NC group were within the
laboratory historical negative control range. A clear, unequivocal and statistically
significant increase in micronuclei was observed in the PC group. The results from
both NC and PC groups confirmed the validity of the assay.
No substantial reduction (i.e. less than 50% the value of the concurrent NC) in the
%RETs was observed for any of the ICG-pHLIP dosed groups, indicating that no
substantial cytotoxicity was observed. Animals dosed with ICG-pHLIP did not show
any statistically significant increases in the %MN-RETs when compared to the
concurrent NC group. Therefore, ICG-pHLIP did not induce cytogenetic damage in
peripheral blood immature erythrocytes in this micronucleus test, when administered
once, by i.v. injection to male rats, up to the maximum practical dose of 25 mg/kg.
In conclusion, ICG-pHLIP showed no evidence of genotoxic activity in this in vivo
study, when tested in accordance with regulatory guidelines.
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In vitro bacterial reverse mutation test
The objective of this study performed at CRL was to determine the potential
genotoxicity of ICG-pHLIP using the bacterial reverse mutation test.
The experimental design was as follows:
Formulation

Dose

Final

Conc.

Volume

Conc.

(µg/mL)

(µL)

(µg/plate)

No. of Replicates
No. of

Dose No.

Negative

0S9

+S9

Strains

-

3

3

5

100
-

Control*
1/ ICG-pHLIP 500

3.16

1.58

3

3

5

1/ ICG-pHLIP 500

10

5.0

3

3

5

1/ ICG-pHLIP 500

31.6

15.8

3

3

5

1/ ICG-pHLIP 500

100

50

3

3

5

2/ ICG-pHLIP 1581

100

158

3

3

5

3/ ICG-pHLIP 5000

100

500

3

3

5

4/ ICG-pHLIP 15811

100

1581

3

3

5

5/ ICG-pHLIP 50000

100

5000 **

3

3

5

Positive

100
***

3

3

5

***

controls
*

vehicle, dimethyl sulfoxide (DMSO), was used as a negative control

**

the OECD/ICH S2(R1) standard limit dose (usually 5000 µg/plate).

***

dose depended on the test strain, the positive controls and methodology used.

Salmonella typhimurium strains (TA1535, TA1537, TA98, TA100 and TA102) were
treated with ICG-pHLIP at a range of concentrations up to 5000 µg/plate (the standard
limit dose for this assay), in the presence and absence of a supplemented rat liver
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fraction (S9 mix), using the plate incorporation version of the bacterial reverse
mutation test.
Bacteria were incubated with standard positive controls, and the response of the
various bacterial strains to these agents confirmed the sensitivity of the test system and
the activity of the S9 mix.
Incomplete, or absent, background lawns of non-revertant bacteria, or substantial
reductions in revertant colony counts, were not obtained following exposure to ICG pHLIP, indicating that ICG-pHLIP was non-toxic to the bacteria at the levels tested.
No precipitation was observed in the assay.
No substantial increases in revertant colony numbers were obtained with any of the
tester strains, following exposure to ICG-pHLIP at any dose level, in either the
presence or absence of S9 mix. Therefore, ICG-PHLIP was considered to be negative
for the induction of mutagenicity in this in vitro assay.
In conclusion, ICG-pHLIP did not show any evidence of genotoxic activity in this in
vitro mutagenicity assay when tested in accordance with regulatory guidelines.

In vitro micronucleus test
The objective of this study performed at CRL was to determine the potential
genotoxicity of ICG-pHLIP using an in vitro mammalian cell micronucleus test in
human peripheral blood lymphocytes.
The experimental design was as follows:
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Dose No.

Formulatio Dose

Final

No. of Cultures

n

Conc.

4

Conc. Volume

Hours 4

Hours 24

(µg/mL)

(µL/culture) (µg/mL) (0S9)

(+S9)

(0S9)

-

50

-

2

2

2

1/ ICG-pHLIP 500

10

1.00

2

2

2

1/ ICG-pHLIP 500

20

2.00

2

2

2

1/ ICG-pHLIP 500

40

4.00

2

2

2

2/ ICG-pHLIP 800

50

8.00

2

2

2

3/ ICG-pHLIP 1600

50

16.0

2

2

2

4/ ICG-pHLIP 3200

50

32.0

2

2

2

5/ ICG-pHLIP 6400

50

64.0

2

2

2

6/ ICG-pHLIP 12800

50
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2

2

2

7/ ICG-pHLIP 25600

50

256

2

2

2

8/ ICG-pHLIP 50000

50

500**

2

2

2

10

80

0.16

2

-

-

10

90

0.18

2

-

-

10

100

0.20

2

-

-

20

50

0.20

2

-

-

25

50

0.25

2

-

-

30

50

0.30

2

-

-

Cyclophospha 1000

50

10

-

2

-

mide

1500

50

15

-

2

-

Mitomycin C

10

50

0.10

-

-

2

Negative
Control*

Colcemid

Nocodazole
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Hours

Dose No.

*

**

Formulatio Dose

Final

No. of Cultures

n

Conc.

4

Conc. Volume

Hours 4

Hours 24

(µg/mL)

(µL/culture) (µg/mL) (0S9)

(+S9)

(0S9)

20

50

-

2

0.20

-

Hours

vehicle, dimethyl sulfoxide (DMSO), was used as a negative control
where the high level = 0.5 mg/mL.

Human peripheral blood lymphocytes were treated with ICG-pHLIP at levels up to the
standard limit of 0.5 mg/mL. The high dose for micronucleus assessment was 0.5
mg/mL as no ICG-pHLIP-related cytotoxicity or precipitation was observed in the
assay. The Negative Control results were within the laboratory negative historical
control range. Lymphocytes were also incubated with standard Positive Controls,
which caused statistically significant increases in the proportion of cells with
micronuclei, confirming the sensitivity of the test system and the activity of
the S9 mix. All criteria for a valid assay were therefore met.
Cultures treated with ICG-pHLIP did not show any statistically significant increases
in the incidence of micronucleated binucleate cells. All results were within the
distribution of the laboratory historical negative control data. Therefore, ICG-pHLIP
was considered to be negative for the induction of micronuclei in this in vitro assay.
In conclusion, ICG-pHLIP did not show any evidence of genotoxic activity in the
in vitro micronucleus test in human peripheral blood lymphocytes, when tested in
accordance with regulatory guidelines.

Animal Imaging Studies
All imaging studies on mice were conducted at University of Rhode Island according
to the approved animal protocol AN04-12-011 in compliance with the principles and
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procedures outlined by the National Institutes of Health for the care and use of animals.
All imaging studies in pigs were conducted at the Porcine Laboratory, Sutter Institute
for Medical Research and approved animal protocol STE.10.19 (Stryker Endoscopy
Imaging and Instrumentation Studies).

Imaging of Blood Vessels in Mice
ICG-malemide was conjugated with Cys to form ICG-Cys for use as a control. Single
tail vein administrations of 2.5 nmol of ICG-Cys or ICG-pHLIP in sterile PBS or PBS
with 5% DMSO or 5% Ethanol (vol:vol) (volume of the injection was 100 μl) were
given to athymic female nude mice (strain Hsd Athymic Nude-Foxn1nu) ranging in
age from 5 to 6 weeks (obtained from Envigo RMS Inc). Mice were under gas
anesthesia, and imaging of mouse leg and ear was performed immediately and at
different time points (from 5 min till 120 min) after administration of ICG-Cys or ICGpHLIP using the Stryker 1558 AIM clinical imaging system with L10 AIM Light
Source, 1588 AIM Camera and a 10 mm scope and a Novadaq imaging system. Five
animals per construct were used in the study.

Imaging of Blood Vessels in Pigs
Pigs (50 kg) received ICG-pHLIP dissolved in PBS or PBS containing 5% Ethanol.
Three doses of pHLIP-ICG were administered (dose level 1 is 0.052 mg/kg of ICGpHLIP, dose level 2 is an additional administration of 0.12 mg/kg of ICG-pHLIP and
dose level 3 is an additional administration of 0.24 mg/kg of ICG-pHLIP). Each dose
was injected intravenously in one bolus followed by a saline flush. Endoscopical and
exoscopical imaging was performed at the same time and up to 2 hrs after ICG-pHLIP
administration. Imaging endoscopically was carried out using the Stryker 1688 system
with the L11 light source (808 nm excitation) and adjustable gain. A 10 mm 30 degree
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Stryker AIM laparoscope was used for imaging of animal internal cavities. Open field
imaging was performed using the Stryker SPY-PHI system (805 nm excitation) and
fixed gain. Images and video were recorded on a Stryker Connected OR Hub device.
The 1688 system has three infrared imaging modes: Overlay, Contrast, and ENV.
Overlay mode captures an NIR frame and a white light frame and combines the two to
allow surgeons to have the best fluorescence reference (green) while still operating.
Contrast mode provides the highest signal to noise image for the fluorescence signal
and does not contain any data from the white light frame. ENV mode contains the
white light frame data in a black/white mode and overlays the fluorescence signal in
green to provide a hybrid mode that allows a higher signal to noise ratio view of the
fluorescence image while still retaining enough of a view of the su rrounding tissue to
allow the surgeon to continue to operate. The SPY-PHI system has three infrared
imaging modes: Overlay, Contrast, and CSF (color-segmented fluorescence). CSF
mode is a type of heat map where the fluorescence signal is mapped to color ac cording
to intensity. Contrast mode is noticeably more sensitive to viewers than Overlay or
CSF mode for weaker signals.

Biodistribution and Kinetics
BALB/cAcNHsd mice ranging in age from 5 to 6 weeks obtained from Envigo RMS,
Inc. were used in the study. Mouse mammary 4T1 cancer cells were subcutaneously
implanted in the right flank (8 x 10 5 cells/0.1 mL/flank) of adult female or male mice.
The triple negative 4T1 tumor model closely mimics stage IV of human breast cancer.
When tumors reached 5-6 mm in diameter, single tail vein injections of 0.5 mg/kg of
ICG-pHLIP in sterile PBS, or PBS with 5% DMSO or 5% Ethanol (vol:vol) (volume
of the injection was 100 μl) were performed. Animals were euthanized at time points:
5 min, 1, 2, 4, 6, 16, 26 and 48 hrs after ICG-pHLIP administration. Several animals
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were used for each time point plus seven control animals (no ICG-pHLIP
administration). Tumor, muscles, skin, heart, lungs, liver, spleen, kidneys, brain,
pancreas, bone, stomach, small and large intestines were collected, imaged
immediately after necropsy, weighed, and fast frozen in liquid nitrogen. The ex vivo
imaging of organs was performed using Stryker 1588 AIM endoscopic system with
L10 AIM Light Source, 1588 AIM Camera using a 10 mm scope. The lens was sp aced
4.3 cm away from the surface of the organs within an enclosed (light protected) area.
The NIR fluorescence imaging of each organ was performed at three different laser
intensity settings. The digital images of organs were processed using aour program
written in Python to determine the average level of intensity recorded in the green
channel. Since organs were imaged in the dark on black mats, the background signal
was determined by introducing an intensity threshold. All the pixels with intensity
from the green channel above the set threshold were counted and the average green
intensity per pixel was calculated. For organs for which the highest laser intensity
produced a saturated image, the medium laser intensity images were analyzed, then
converted to a theoretical comparison using experimentally found conversion curves.
The fluorescence signals in organs and tissue were also measured in the tissue/organ
homogenates and compared with the signals from the control tissue/organ
homogenates (collected from control mice) mixed with known amounts of ICGpHLIP. About 100 mg of tissue were homogenized with 2.5x (about 250 µL) volumes
of DMSO using BioMasher II disposable homogenizers (DiagnoCine, LLC). 30 µl of
homogenate was placed into 384 well plate and imaged using an Odyssey IR scanner
(Li-Cor Biosciences). Tissue homogenates of control mice mixed with known
concentrations of ICG-pHLIP were used to establish the calibration curve.
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Imaging Tumors iin Different Tumor Models
Targeting of murine and human tumors was shown in 8 different tumor models in
athymic female nude mice (strain Hsd Athymic Nude-Foxn1nu) ranging in age from 5
to 6 weeks (obtained from Envigo RMS, Inc). The following tumors were established
by subcutaneous injection of 1 x 10 6 cells/0.1 ml/flank in flanks of athymic nude mice:
HeLa (humans cervical adenocarcinoma), M4A4 (human epithelial carcinoma), 4T1
(murine breast tumor), A549 (human lung carcinoma), LLC (murine Lewis Lung
carcinoma), UM-UC3 (human urinary bladder cancer), and 4 x 10 6 cells/0.1 ml/flank
of LNCaP

tumor (human prostate cancer). Human MDA-MB-231

(breast

adenocarcinoma) tumors were established by injections of 1 x 10 6 cells/0.05 ml in the
mammary fat pad. Tumors reached different sizes (from very small (1 -2 mm in
diameter) to large (8-12 mm in diameter) and 100 μl of tail vein injections of 0.5 mg/kg
of ICG-pHLIP in sterile PBS or PBS containing either 5% of DMSO or 5% of Ethanol
were performed. Imaging was carried at 24 hours after ICG-pHLIP administration.
White light and NIR whole-body imaging were performed while the animal was under
gas (isoflurane) anesthesia using a Stryker 1558 AIM clinical imaging system with
L10 AIM Light Source, 1588 AIM Camera and a 10 mm scope. Next, the skin was
removed from the tumor side and whole-body imaging of live animals was performed
with the skin removed from the tumor side. Finally, surgery was carried out under
fluorescence-guidance to remove tumor and image tumor bed using Stryker SPY-PHI
handheld clinical imaging system.

Histopathology
Tumors with surrounding muscle were frozen in tissue-tek OCT compound using
liquid nitrogen and stored at -80°C until sectioned using a cryostat at -25°C (Thermo
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Scientific HM525 NX) at a 5 µm thickness. The tumor slides were fixed in 4%
formaldehyde and stained with hematoxylin and eosin (H&E) (Thermo Fisher
Scientific and Poly Scientific R & D Corp). Some sections were covered with a drop
of mounting medium (Permount®, Fisher Scientific) and then a cover slide was placed
over the medium. Stained and non-stained sections were imaged using an Odyssey IR
scanner (Li-Cor Biosciences), Styker imaging system, and inverted microscope
"Invitrogen EVOS FL Auto 2" using 4x and 10x objectives. Tiled HE images were
made using "Invitrogen EVOS FL Auto 2.0 Imaging System" software.
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TABLES

Table

S1.

Qualification of GLP

ICG-pHLIP

verification batch #1912127

manufactured by CordenPharma, GmbH.
Characteristic

Test
Metho

Results
Specification

d
Appearance
Identity

Visual
LCMS

Green powder

conforms

1382.9 [M+3H]3+/3 ± 1 amu

conforms

Elution

peak

with

5%

Identity

HPLC

Purity, (p)

HPLC

>98.5%

98.6%

Impurities

HPLC

Total Imp.: NMT 1.5%

1.4%

Acetic Acid Content

IC

 5%

4.4%

TFA Content

IC

Determine and report

0.01%

Photo-Assay

NIR

0.8 ∙ 𝑝 ∙ 𝑘  OD  1.11 ∙ 𝑝 ∙ 𝑘

0.85

deviation

conforms

DMF < 100
ppm
ACN < 50
ppm
Residual solvents

GC

Determine and report

i-hexane

<

50 ppm
MTBE < 50
ppm
DCM < 50
ppm

Water content

KF

Determine and report

Peptide Content (k)

CHN

Determine and report
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1.55%
N
12.6%

(total):

Peptide
content: 91%
0.79%
Cation Content, NH 4+

IC

Determine and report

(correlates to
0.6% N)

Cation Content, Na +
Peptide

Content/Amino

Acid Composition

IC

Determine and report

<0.01%

AAA

Conforms to theory

87.6%
Conforms to

Peptide Sequence

MS/M
S

Conforms to theory

theory,
beside AA 1
and 2

LC-MS - liquid chromatography - mass spectrometry; HPLC - high performance liquid
chromatography; IC – ion chromatography; GC – gas chromatography; KF - KarlFischer titration; CHN – carbon, hydrogen, nitrogen element analysis; AAA – amino
acid analysis with St.D. <10%; MS/MS – tandem mass spectrometry.
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Table S2. The bound and unbound fractions of ICG-pHLIP treated with whole blood
or plasma.
Whole-blood

Plasma

Plasma

bound

bound

unbound

fraction

fraction

fraction

Human

>99.9%

>99.9%

<0.1%

Mouse

>99.9%

95.3%

4.8%

Rat

>99.9%

96.6%

2.3%

Dog

>99.9%

98.8%

1.2%

Minipig

>99.9%

99.3%

0.7%

Cyno

>99.9%

99.6%

0.4%
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Table S3. Concentration of ICG-pHLIP (µg/mL) in blood of mice and dogs at different
time points after single i.v. administration of 12.3 mg/kg of ICG-pHLIP to mice and
0.064 mg/kg of ICG-pHLIP to dogs.
Time

post-

Concentration of ICC- Concentration
pHLIP in mice blood,

pHLIP

µg/mL

µg/mL

0.08

1.347 ± 0.092

275.4 ± 7.5

0.25

1.230 ± 0.082

251.5 ± 13.9

0.5

1.123 ± 0.089

239.8 ± 6.3

1

0.882 ± 0.099

217.0 ± 8.9

2

0.749 ± 0.065

144.0 ± 13.1

4

0.432 ± 0.056

102.6 ± 4.8

6

0.319 ± 0.041

68.7 ± 1.3

8

0.207 ± 0.032

58.8 ± 14.0

12

0.118 ± 0.008

-

16

-

14.6 ± 2.6

dose, hours
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in

of
dog

ICGblood,

Table S4. Fluorescence intensity (a.u.) obtained by ex vivo imaging of organs collected
at different time points after i.v. administration of ICG-pHLIP into female Balb/C mice
bearing 4T1 tumors in right flank.
16
Organ/Time

Tumor

Liver

Kidneys

Heart

5 min

1 hr

2 hrs

4 hrs

6 hrs

48
26 hrs

hrs

hrs

46.3

92.0

119.7

205.3 193.8

208.2 173.3

135.5

37.2

117.6

145.3

219.5 169.3

226.8 208.2

167.0

32.4

73.8

151.9

191.8 250.5

233.9 182.1

152.0

33.4

61.1

121.8

206.4 172.1

214.5 174.8

31.7

157.9

131.1

233.0 207.3

230.6 174.4

111.6

215.3

166.6

197.1

174.4

136.3

380.8

541.2

560.0

532.7 517.1

382.1 213.8

154.4

393.6

558.6

568.2

569.4 560.7

386.3 196.9

151.2

469.0

519.7

555.7

541.0 489.1

455.1 217.1

143.2

450.4

520.5

523.6

539.5 483.9

368.5 214.9

405.4

525.1

505.3

517.6 584.9

410.3 223.0

540.6

217.6

553.0

209.6

593.2

215.9

145.9

202.1

175.6

191.7 169.6

154.1 121.4

52.0

180.2

202.8

161.0

188.5 169.3

175.2 100.2

71.4

165.6

179.8

152.4

175.7 173.3

183.1 108.4

73.9

195.7

199.0

154.4

183.6 180.9

160.3 115.2

171.2

184.9

136.8

188.0 176.9

180.4 113.8

174.5

188.4

164.5

178.3

117.7

171.0

117.0

172.9

118.7

191.7 153.6
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128.2 67.8

23.3

Lungs

Brain

Spleen

Pancreas

213.0

194.5

154.9

191.6 166.7

115.2 50.1

23.3

211.8

170.2

183.9

174.5 155.5

146.4 63.4

23.0

191.5

155.5

176.2

182.8 166.5

112.3 61.5

199.6

189.6

158.3

187.5 173.0

143.6 63.6

179.0

42.8

181.5

52.1

175.9

57.9

214.0

194.4

176.4

187.1 150.6

132.0 54.4

31.5

218.3

202.2

163.5

209.3 165.3

115.2 54.5

35.8

220.4

192.7

172.4

163.7 141.9

169.5 81.1

35.2

215.4

185.8

180.7

196.1 180.4

133.2 53.2

214.8

198.5

191.7

179.0 145.7

156.4 77.6

171.3

76.0

159.0

69.3

161.4

57.9

137.0

126.7

95.4

73.2

50.6

36.1

0

0

153.9

151.5

79.9

78.5

48.7

37.9

0

0

196.2

138.1

96.9

60.0

47.9

35.6

0

0

172.2

136.8

53.8

76.5

55.2

33.7

0

175.6

135.4

84.8

81.0

74.3

33.3

0

78.8

0

84.6

0

92.5

0

146.1

158.7

134.3

158.3 133.6

102.2 39.9

21.9

154.8

162.3

144.2

167.2 160.9

101.4 40.6

22.0

168.9

161.1

135.4

143.8 152.7

150.1 50.7

21.9

147.9

151.4

144.6

140.0 134.0

92.5

155.5

155.5

126.2

145.2 159.3

135.3 58.1

169.1

163.4

121.6

50.8

144.4

60.1

138.4

65.4

155.3

43.6

101.6 70.7

144

72.6

46.5

0

Bone

Stomach

176.4

-

96.2

80.2

62.0

49.6

38.4

0

186.6

140.5

41.3

96.3

87.1

121.2 34.2

0

129.0

119.1

111.3

77.4

96.3

49.5

35.4

104.9

107.9

74.8

104.7 95.1

58.6

0

93.5

0

89.1

42.6

81.9

28.3

73.8

67.3

40.3

90.1

58.7

76.7

43.1

44.3

73.1

92.8

62.5

35.6

73.6

73.4

45.4

55.2

88.8

77.0

48.3

55.3

61.2

58.3

42.3

40.5

73.4

75.5

96.1

57.5

49.2

64.5

50.2

87.8

57.5

40.4

76.9

90.8

58.2

32.8

80.1

68.2

31.2

60.2

78.8

63.8

72.8

125.1

49.9

98.5

82.5

81.7

91.1

104.2

71.8

99.6
99.3

126.8

103.5 42.2

25.6

107.6 129.7

86.3

48.3

36.9

79.9

109.5 141.6

161.0 71.0

30.7

98.0

98.4

116.4 119.8

92.1

118.8

84.3

110.3 116.1

143.6 72.0

62.2

136.5

52.3

126.1

47.9

66.8

49.6

62.2

78.3

64.3

83.5

40.4

77.6

34.3

0

45.5

97.2

57.8

54.9

58.8

107.8 43.8

0

38.4

68.8

31.5

42.1

44.2

78.6

35.8

22.7

Small

33.0

62.1

45.4

73.1

68.2

80.9

41.6

intestine

33.0

53.0

36.3

70.8

59.5

74.2

33.2

67.0

73.0

71.1

64.6

44.8

61.5
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42.4

49.1

0

0

32.3

37.1

0

0

35.4

32.5

32.2

39.4

33.4

42.6

0

0

30.0

33.3

0

0

30.0

37.8

0

0

Large

47.8

27.0

0

0

39.8

36.6

0

intestine

29.8

0

0

0

0

45.2

0

Skin

Muscle

44.0

24.9

33.6

27.6

23.2

0

40.6

32.0

40.9

66.9

34.5

91.1

0

37.7

1.0

39.4

43.4

51.0

66.1

60.5

31.9

0

38.0

54.1

0

38.5

56.3

82.5

0

0

33.4

38.2

36.8

39.6

37.3

50.7

57.0

27.6

32.1

39.0

45.1

41.2

98.9

36.4

51.7

137.2

59.7

24.6

41.5

29.2

36.5

0

0

36.2

0

0

0

0

1.0

40.8

0

0

0

0

0

0

1.0

0

0

41.7

0

0

42.9

0

38.6

0

0

0

0

0

0

35.9

0

0

53.0

0

0

0

27.2

64.9

25.5

0

0

0
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Table S5. Mean (and St. D.) of fluorescence intensity values presented in Table S4.
Organ/

5 min

1 hr

2 hrs

4 hrs

6 hrs

16 hrs

26 hrs

48 hrs

36.2±

100.5

133.9±

188.6

198.6

222.8

182.7

151.5

6.0

±38.5

14.2

±38.1

±33.0

±11.0

±24.8

±15.7

419.8

533.0

542.6±

548.4

527.1

400.5

213.6

149.6

±37.9

±16.7

26.8

±23.5

±44.4

±34.1

±7.7

±5.8

Kidney

171.7

193.7

156.0±

181.2

174.0

170.6

114.0

65.8±

s

±18.4

±10.6

14.1

±7.8

±5.0

±12.8

±6.8

12.0

198.1

179.6

167.6±

183.1

163.0

129.2

57.4±

23.2±

±15.9

±16.4

12.2

±6.7

±8.2

±15.7

8.4

0.2

216.6

194.7

177.0±

178.4

156.8

141.3

65.5±

34.1±

±2.7

±6.2

10.4

±18.0

±15.9

±21.5

11.7

2.3

167.0

137.7

82.2±1

78.1±

55.3±

35.3±

0.0±0.

0.0±0.

±22.5

±8.9

7.4

9.4

11.0

1.8

0

0

154.6

157.8

136.9±

149.1

148.1

116.3

51.1±

21.9±

±9.0

±4.4

7.7

±10.1

±13.4

±25.0

9.5

0.0

Pancre

153.2

132.7

89.0±3

90.6±

82.2±

70.3±

28.2±

0.0±0.

as

±34.7

±24.5

2.0

10.1

15.3

30.0

18.2

0

79.4±

74.0± 57.5±2

63.2±

66.7±

66.2±

50.8±

46.7±

8.1

13.1

21.8

16.0

8.5

12.2

7.6

Stomac

91.7±

99.1± 80.7±1

108.9

126.8

117.3

55.7±

31.0±

h

13.4

23.0

±20.7

±9.9

±33.1

11.3

5.7

S.

42.4±

71.9± 47.1±1

63.4±

54.2±

83.8±

48.5±

7.6±1

Intest.

12.2

16.9

14.6

11.6

13.6

15.6

3.1

L.

37.1±

28.4± 6.4±14. 17.5±

27.1±

40.5±

6.6±1

0.0±0.

Intest.

7.9

17.9

19.6

15.6

4.0

2.2

0

27.9±

39.1± 32.0±1

49.2±

47.1±

76.7±

39.5±

12.6±

16.4

9.0

10.1

13.6

20.4

43.7

21.8

22.2±

8.2±1

22.9±

0.0±0.

0.0±0.

13.5±

0.0±0.

20.3

8.2

20.8

0

0

25.6

0

Time
Tumor

Liver

Heart

Lungs

Brain

Spleen

Bone

Skin

Muscle

3.4

8.6

3.9

4

8.1
0.0±0.0
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Figures

Figure S1. (a) HPLC chromatogram of ICG-pHLIP used in PoC and toxicology
studies. (b) The spiking experiment: ICG-pHLIP synthesized by CordenPharma
according to the optimized protocol was spiked with ICG-pHLIP shown on panel a in
ratio of 1:1, dissolved in ACN/water/Tween20 in a ratio of 50:50:0.02 containing 5
mM tri potassium-EDTA and analyzed using the standard analytical method. The
HPLC chromatogram provides a single signal, consistent with the compliance of both
substances. (c) The mass spectrum of ICG-pHLIP synthesized by CordenPharma is
shown.
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Figure S2. Normalized absorbance spectrum of ICG-pHLIP in methanol (a),
absorbance and fluorescence spectra of Isosulfan Blue (IB) in water, Methylene Blue
(MB) in PBS, and absorbance spectra of ICG-pHLIP (ICG) in DMSO (b). Color image
of mouse received intra-tumoral injection of Isosulfan Blue (c). NIRF image of the
same mouse followed by intra-tumoral injection of ICG-pHLIP (d). Overlay of color
and NIRF ICG-pHLIP images (e) and color image of the same mouse after
administration of both IB and ICG-pHLIP (f). The data clearly demonstrate that the
administration of ICG-pHLIP does not obstruct IB or MB visualization.
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Figure S3. Inhibition response curves obtained in a radio ligand binding assay after
treatment of progesterone B with increasing concentrations of ICG-pHLIP and R-5020
(a known progesterone B agonist) for 20 hrs. The experiments were performed by
Eurofins Panlabs, Inc.
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Figure S4. Fluorescence angiography with ICG-pHLIP. Mice under gas anesthesia
received a single tail vein injection of 0.5 mg/kg of ICG-pHLIP followed by imaging
within 2 hrs using a Novadaq imaging system. The signal was recorded from the mouse
ear (a) and leg (b).
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Figure S5. Imaging of blood vessels in pigs. NIR ICG-pHLIP fluorescent images of
blood vessels at different time points after a single i.v. injection of ICG -pHLIP are
shown. Imaging inside the pig body cavity was performed using a Stryker system for
endoscopic/laparoscopic imaging (a). Imaging of a pedicle flap was performed using
a Stryker for open field imaging (b).
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Figure S6. Photo image of Balb/C mouse bearing 4T1 tumors in both flanks (a-b) or
in a single flank (c-d) with skin removed from the tumor site (a, c). Overlays of photo
and NIR ICG-pHLIP fluorescent images are shown (b, d) (tumors are indicated by
arrows). ICG-pHLIP was administrated as a single i.v. injection (0.5 mg/kg), imaging
was performed 24 hrs post-dose while animal was under gas anesthesia and was
euthanized immediately after imaging.
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Figure S7. Tissue/organ mean surface fluorescence calculated from NIR ICG-pHLIP
fluorescent images for each mouse (the representative images are shown on Figure 4
and numbers are given in Table S4) and the calculated mean values o f fluorescence
(numbers are presented in Table S5) are shown for different time points post-dose of
ICG-pHLIP.
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Figure S8. Photo images and overlay of photo and NIR ICG-pHLIP fluorescent
images of athymic nude mice bearing human and murine tumors. ICG-pHLIP was
administrated as a single i.v. injection (0.5 mg/kg), imaging was performed 24 hrs postdose, while the animal was under gas anesthesia. Tumors are indicated by arrows.
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Figure S9. Each row contains an HE image, a NIR ICG-pHLIP fluorescent image, and
an overlay of HE and NIR ICG-pHLIP images. UMUC3 human urinary transitional
carcinoma (a) and 4T1 murine mammary cancer (b) tumors were grown in flanks of
nude mice. ICG-pHLIP was administrated as a single i.v. injection (0.5 mg/kg) .
Animals were euthanized 24 hrs post-dose, tumors were collected, frozen, and cryosectioned. Each second section was stained with HE. HE sections were imaged using
a Stryker instrument and NIR imaging was performed using an Odyssey IR scanner.
The correlation between tumor location (dark blue) and fluorescent signal is
demonstrated.
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